

①



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪

Publication number:

0 206 415
A2

⑫

EUROPEAN PATENT APPLICATION

⑰

Application number: 86201048.5

⑱

Date of filing: 17.06.86

⑤

Int. Cl.⁴: **C 07 D 473/00**, C 07 D 473/30,
C 07 D 473/40, C 07 D 519/00,
A 61 K 31/52
//
(C07D519/00, 473:00, 471:00),
(C07D519/00, 513:00, 473:00)

③

Priority: 24.06.85 GB 8515934

⑦

Applicant: **JANSSEN PHARMACEUTICA N.V.**,
Turnhoutsebaan 30, B-2340 Beerse (BE)

④

Date of publication of application: 30.12.86
Bulletin 86/52

⑧

Designated Contracting States: **AT BE CH DE FR GB IT LI**
LU NL SE

⑦


Inventor: **Janssens, Frans Eduard**, Tinststraat 79,
B-2830-Bonheiden (BE)
Inventor: **Diels, Gaston Stanislas Marcella**,
Oosteinde 12, B-2380-Ravels (BE)

⑤


(4-Piperidinylmethyl and -hetero)purines.

⑤

Novel (4-piperidinylmethyl and hetero)purines of
formula



wherein $-A^1 = A^2 = A^3 = A^4-$ is $-N=CH-N=CH-$ or
 $-CH=N-CH=N-$ and L is a radical $L^1-C_rH_{2r}-T^1-C_sH_{2s}-$ or



the pharmaceutically acceptable acid addition salts and
possible stereochemically isomeric forms thereof, which
compounds are anti-allergic agents; pharmaceutical com-
positions containing such compounds as an active ingre-
dient and methods of preparing said compounds and phar-
maceutical compositions.

0666

JAB 476

5

10

15

(4-PIPERIDINYLMETHYL AND -HETERO)PURINES.

20 Background of the invention:

In U.S. Patent No. 4,219,559 there are described a number of N-heterocyclyl-4-piperidinamines having antihistaminic properties.

In European Patent Publication Nos. 0,099,139; 0,145,037 and 0,144,101 there are also described a number of N-heterocyclyl-4-
25 piperidinamines as compounds having antihistaminic and serotonin-
antagonistic properties.


The compounds of the present invention differ from the prior art compounds essentially by the nature of the 4-piperidinyl substituent which is invariably a purinylmethyl or -hetero group.

30

Description of the preferred embodiments:

This invention is concerned with novel (4-piperidinylmethyl and -hetero)purines which may structurally be represented by the formula

35



the pharmaceutically acceptable acid addition salts and the possible stereochemically isomeric forms thereof, wherein:

5 $-A^1=A^2-A^3=A^4-$ is a bivalent radical having the formula



10 wherein one or two hydrogen atoms in said radicals (a-1) or (a-2) may, each independently from each other, be replaced by halo, C_{1-6} alkyl, C_{1-6} alkyloxy, trifluoromethyl or hydroxy;

R^1 is a member selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-6} cycloalkyl, Ar^1 and C_{1-6} alkyl substituted with one
15 or two Ar^1 radicals;

R^2 is a member selected from the group consisting of hydrogen and C_{1-6} alkyl;


B is CH_2 , NR, O, S, SO or SO_2 ; said R being a member selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl,
20 $(C_{1-6} \text{ alkyl})-CO-$, $(C_{1-6} \text{ alkyloxy})-CO$ and Ar^2-C_{1-6} alkyl;

L is a member selected from the group consisting of a radical of formula



25

a radical of formula



30


wherein one or two hydrogen atoms in the bivalent radical

$-C_{sH_{2s}}-$ may, each independently from each other, be replaced by halo, hydroxy, mercapto, isothiocyanato, isocyanato, C_{1-6} alkyloxy, C_{1-6} alkylthio, Ar^1 , Ar^1O- , Ar^1S- , Ar^1SO_2- , or NHR^3R^5 ; and
35 n is 0 or the integer 1 or 2;

r and s are, independently from each other, 0 or an integer of from 1 to 6 inclusive;

5 T is -Y- or $-Z-\overset{\overset{X}{\parallel}}{C}-Y-$;

- T¹ is $-\overset{\overset{X}{\parallel}}{Z}-C-$ or a direct bond;
 said Y being O, S, NR³ or a direct bond;
 10 X being O, S, CH-NO₂ or NR⁴;
 Z being O, S, NR⁵ or a direct bond; and
 said R³ being hydrogen, C₁₋₆ alkyl, Ar²-C₁₋₆ alkyl, 2-(C₁₋₆ alkyloxy)-1,2-dioxoethyl or a radical of formula -C(=X)-R⁶, R⁶ being hydrogen, C₁₋₆ alkyl, Ar², Ar²-C₁₋₆ alkyl, C₁₋₆ alkyloxy,
 15 Ar²-C₁₋₆ alkyloxy, mono- or di(C₁₋₆ alkyl)amino, Ar²-amino, Ar²-C₁₋₆ alkylamino or Ar²-C₁₋₆ alkyl(C₁₋₆ alkyl)amino;
 said R⁴ being hydrogen, C₁₋₆ alkyl, cyano, nitro, Ar²-sulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl or Ar²-carbonyl; and
 said R⁵ being hydrogen or C₁₋₆ alkyl;
 20 wherein L¹ is a member selected from the group consisting of hydrogen; halo; hydroxy; C₁₋₆ alkyloxy; C₁₋₆ alkylthio; cyano; mercapto; isocyanato; isothiocyanato; Ar¹; Ar¹-carbonyl; Ar¹-sulfonyl; C₁₋₆ alkylsulfonyl; C₃₋₆ cycloalkyl being optionally substituted with up to two substituents each independently selected from the group
 25 consisting of C₁₋₆ alkyl, cyano and Ar²; [10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5-ylidene]methyl; Het; and furan substituted with substituted C₁₋₆ alkyl; said substituted C₁₋₆ alkyl being C₁₋₆ alkyl substituted with a member selected from the group consisting of hydroxy, mercapto, C₁₋₆ alkyloxy, C₁₋₆ alkylthio, aminoc₁₋₆
 30 alkylthio, Ar²-oxy and a radical of formula



(c),

wherein: t is 0 or an integer of from 1 to 6 inclusive; and
 R^7 is hydrogen or C_{1-6} alkyl;
 provided that: when in said radical of formula (c) t is
 5 0, then Z or Y is a direct bond; and

where r is 0, L^1 may also be C_{2-6} alkenyl, Ar^1-C_{2-6} alkenyl or
 C_{1-6} alkyl substituted with two C_{1-6} alkyloxy radicals; and

10 where r is 0 and T is NR^3 , or T is $-N(R^5)-C(=X)-Y$ or T^1 is $-N(R^5)-C(=X)-$,
 L^1 may also be amino, C_{1-6} alkylamino or Ar^1 -amino; and

where r is 0, and T is $-N(R^5)-C(=X)-Y$ or T^1 is $-N(R^5)-C(=X)-$,
 L^1 may also be nitro;

15

said Het being an optionally substituted five- or six-membered hetero-
 cyclic ring, being optionally condensed with an optionally substituted
 five- or six-membered carbocyclic or heterocyclic ring;

20 provided that:

- i) when L is a radical of formula (b-1) wherein L^1 is hydrogen and
 wherein T is $-Z-C(=X)-Y$ wherein Y is other than a direct bond
 and Z and X are each independently O or S, then r is not 0; or
 when L is a radical of formula (b-2) wherein L^1 is hydrogen and
 25 wherein T^1 is $-Z-C(=X)-$ wherein Z and X are each independently
 O or S, then r is not 0;
- ii) when L is a radical of formula (b-1) wherein L^1 is halo,
 hydroxy, C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio, isocyanato,
 isothiocyanato or Het connected to C_rH_{2r} on a nitrogen atom,
 30 and wherein r is 0, then T is a direct bond or a radical
 $-C(=X)-Y-$; or when L is a radical of formula (b-2) wherein L^1
 is halo, hydroxy, C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio,
 isocyanato, isothiocyanato or Het connected to C_rH_{2r} on a
 nitrogen atom, and wherein r is 0, then T^1 is a radical $-C(=X)-$;

iii) when L is a radical of formula (b-1) wherein T is Y, said Y being other than a direct bond, or wherein T is $-Z-C(=X)-Y-$, wherein Y is other than a direct bond, then s is not 0;

5 wherein Ar^1 is a member selected from the group consisting of phenyl, substituted phenyl, naphthalenyl, thienyl, halothienyl, C_{1-6} alkylthienyl, pyridinyl, mono- and di(C_{1-6} alkyloxy)pyridinyl, pyrrolyl, C_{1-6} alkylpyrrolyl, furanyl, furanyl substituted with C_{1-6} alkyl, pyrazinyl, thiazolyl, imidazolyl, C_{1-6} alkylimidazolyl;
 10 said substituted phenyl, being phenyl substituted with up to 3 substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylthio, mercapto, amino, mono- and di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonyl C_{1-6} alkyl, phenyl C_{1-6} alkylsulfonyl, phenylsulfonyl C_{1-6} alkyl, a radical of
 15 formula $R^8-C_pH_{2p}-Y-$, a radical of formula $R^9-Z-C(=X)-Y-$, and a radical of formula $R^{10}SO_2Y-$; wherein p is an integer of from 1 to 6 inclusive and R^8 is a member selected from the group consisting of amino, cyano, phenyl aminocarbonyl, mono- and di(C_{1-6} alkyl)amino-
 20 carbonyl, C_{1-6} alkyloxycarbonyl, phenyl C_{1-6} alkyloxycarbonyl, 4-morpholinylcarbonyl, 1-piperidinylcarbonyl, 1-pyrrolidinylcarbonyl, and C_{2-6} alkenyl; wherein R^9 is member selected from the group consisting of hydrogen, C_{1-6} alkyl and Ar^2 ; provided that, when R^9 is hydrogen and Y is other than a direct bond, then Z is not O or
 25 S; and wherein R^{10} is C_{1-6} alkyl or Ar^2 ;

wherein Ar^2 is a member selected from the group consisting of phenyl, substituted phenyl, thienyl and furanyl, said substituted phenyl being phenyl optionally substituted with up to three substituents each independently selected from the group consisting of
 30 halo, hydroxy, nitro, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylthio, mercapto, amino, mono- and di(C_{1-6} alkyl)amino, carboxyl, C_{1-6} alkyloxycarbonyl and (C_{1-6} alkyl)-CO.

As used in the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; the term " C_{1-6} alkyl" is meant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like; " C_{1-10} alkyl" is meant to include C_{1-6} alkyl radicals, as defined hereinabove, and the higher homologs thereof having from 7 to 10 carbon atoms; the term " C_{2-6} alkenyl" is meant to include straight and branch chained hydrocarbon radicals having from 2 to 6 carbon atoms, such as, for example, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and the like; the term " C_{3-6} cycloalkyl" is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; and " C_{1-6} alkanediyl" is meant to include bivalent straight or branch chained alkanediyl radicals having from 1 to 6 carbon atoms.

15

Preferred compounds within the invention are those wherein Het is a five- or six-membered heterocyclic ring containing a number of heteroatoms which varies of from 1 to 4, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, provided that no more than two oxygens or sulfurs are present, said five or six-membered ring being optionally condensed with a five- or six-membered carbocyclic or heterocyclic ring also containing a number of heteroatoms which varies from 1 to 4, the latter heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, provided that no more than 2 oxygens or sulfurs are present, and wherein said Het being a bicyclic ring system may optionally be substituted with up to 6 substituents, or said Het being a monocyclic ring system may optionally be substituted with up to 3 substituents, said substituents of Het being selected from the group consisting of a bivalent radical of formula $=X$, said $=X$ independently having the same meaning of the previously defined X; halo; isocyanato; isothiocyanato; nitro, cyano, trifluoromethyl; a radical of formula $A-Y-$, wherein A is hydrogen, Ar^1 or C_{1-6} alkyl being optionally substituted with Ar^1 , C_{1-6} alkyloxy, Ar^1O , hydroxy, C_{1-6} alkyloxycarbonyl and Y independently has the same meaning of the previously defined Y; and a

35

radical A Z-C(=X)-Y-, wherein A is as defined hereinabove and Z, X and Y independently have the same meanings of the previously defined Z, X and Y; provided that (i) when in the radical A-Y- A is hydrogen, then Y is other than a direct bond, or (ii) when in the radical A-Z-C(=X)-Y-
 5 A is hydrogen and Y is NR³, O or S, then Z is other than O or S.

Particularly preferred compounds within the invention are those wherein Het is a member selected from the group consisting of

- 1) pyridinyl which is optionally substituted with one or two substituents each independently selected from the group consisting of
 10 halo, amino, mono- and diC₁₋₆ alkyl amino, Ar² C₁₋₆ alkyl-amino, nitro, cyano, aminocarbonyl, C₁₋₆ alkyl, C₁₋₆ alkyloxy, C₁₋₆ alkylthio, C₁₋₆ alkyloxycarbonyl, hydroxy, C₁₋₆ alkylcarbonyloxy, Ar²-C₁₋₆ alkyl and carboxyl;
 15 pyridinyloxy optionally substituted with nitro;
 quinolinyl which is optionally substituted with C₁₋₆ alkyl;
 pyrimidinyl which is optionally substituted with one or two substituents each independently selected from the group consisting of halo, amino, hydroxy, C₁₋₆ alkyl, C₁₋₆
 20 alkyloxy, C₁₋₆ alkylthio and Ar²-C₁₋₆ alkyl;
 quinazolinyl which is optionally substituted with hydroxy or C₁₋₆ alkyl;
 pyridazinyl which is optionally substituted with C₁₋₆ alkyl or halo;
 25 quinoxalinyl which is optionally substituted with C₁₋₆ alkyl;
 pyrazinyl which is optionally substituted with halo, amino or C₁₋₆ alkyl;
 phthalazinyl which is optionally substituted with halo;
 morfolinyl;
 30 thiomorfolinyl;
 piperidinyl;
 2,3-dihydro-3-oxo-4H-benzoxazinyl and 2,3-dihydro-1,4-benzodioxinyl, both being optionally substituted with C₁₋₆ alkyl or halo;
 35 dioxanyl being optionally substituted with C₁₋₆ alkyl;

2-oxo-2H-1-benzopyranyl and 4-oxo-4H-1-benzopyranyl both being optionally substituted with C₁₋₆ alkyl;

1,4-dihydro-2,4-dioxo-3(2H)-pyrimidinyl being optionally

5 substituted with C₁₋₆ alkyl; and

4-oxo-2(1H)-pyrimidinyl;

ii) 5,6-dihydro-4H-1,3-thiazin-2-yl, thiazolyl, 4,5-dihydrothiazolyl,

oxazolyl, imidazolyl, tetrazolyl, 1,3,4-thiadiazolyl, benzimi-

10 dazolyl, benzothiazolyl, benzoxazolyl, 4,5-dihydro-5-oxo-1H-

tetrazolyl, 2-oxo-3-oxazolidinyl and indolyl whereby each of the Het-radicals of group ii) may optionally be substituted where possible with up to two substituents selected from the group


consisting of C₁₋₆ alkyl, Ar¹, Ar¹-C₁₋₆ alkyl, benzimida-

15 zolylC₁₋₆ alkyl, amino, (aminoiminomethyl)amino, mono- and


di(C₁₋₆ alkyl)amino, Ar¹-amino, nitro, C₁₋₆ alkyloxy-carbonyl and pyrimidinyl;

iii) a radical of formula



20





25






30



35





5

wherein each X^2 is independently O or S;

- R^{11} , R^{12} , R^{14} , R^{22} and R^{24} are each independently hydrogen, C_{1-6} alkyl, Ar^2-C_{1-6} alkyl, hydroxy C_{1-6} alkyl or C_{1-6} alkyloxycarbonyl;
- 10 R^{13} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} and R^{23} are each independently hydrogen, C_{1-6} alkyl, hydroxy, mercapto, C_{1-6} alkyloxy, C_{1-6} alkylthio, halo and (C_{1-6} alkyloxycarbonyl) C_{1-6} alkyl;
- G^1 is $-CH=CH-CH=CH-$, $-S-CH=CH-$ or $-N=CH-NH-$;
- G^2 is $-CH=CH-CH=CH-$, $-S-(CH_2)_2-$, $-S-(CH_2)_3-$, $-(CH_2)_4-$ or $-S-CH=CH-$;
- 15 G^3 is $-CH=CH-CH=CH-$, $-CH_2-NH-(CH_2)_2-$, $-S-CH=CH-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ or $-CH=N-CH=N-$;
- G^4 is $-CH_2-NH-(CH_2)_2-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ or $-CH=N-CH=N-$;
- G^5 is $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ or $-CH=N-CH=N-$;
- 20 G^6 is $-CH=CH-CH=CH-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ or $-CH=N-CH=N-$;

wherein one or two hydrogen atoms in said radicals G^1 , G^2 , G^3 , G^4 , G^5 or G^6 or in the benzene part of the radicals of formula (e-2), (e-3) or (e-9) may be replaced by C_{1-6} alkyl, C_{1-6} alkylthio, C_{1-6} alkyloxy or halo where said hydrogen atom is bonded on a carbon atom, or by C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, Ar^2-C_{1-6} alkyl, where said hydrogen is bonded on a nitrogen atom.

30

It is clear that R^{11} , R^{12} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{22} or R^{23} is absent where the radical of formula (e-1), respectively (e-4), (e-5), (e-6) or (e-7) is connected to C_sH_{2s} on the atom bearing R^{11} , R^{12} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{22} or R^{23} .

35

More particularly preferred compounds within the invention are those wherein L is a radical of formula (b-1).

Especially preferred compounds within the invention are those more particularly preferred compounds wherein Het is as described hereinabove for the particularly preferred compounds, wherein r is 0 and L¹ is hydrogen, hydroxy, C₁₋₆ alkyloxy, C₁₋₆ alkylthio, mercapto, Het, Ar¹, isocyanato, isothiocyanato or cyano.


More especially preferred compounds within the invention are those especially preferred compounds wherein R¹ is C₁₋₆ alkyl substituted with one Ar¹ radical.

It is evident that in the compounds of formula (I) wherein L¹ is Het, said Het may be unsaturated or partly or completely saturated.


15

The compounds of formula (I) wherein Het is a heterocycle which is substituted with a hydroxy, mercapto or amino radical may contain in their structure a keto-enol tautomeric system or a vinylog system thereof, and consequently these compounds may be present in their keto form as well as their enol form.

The compounds of formula (I) can generally be prepared by reacting a piperidine of formula (II) with a diamine of formula (III).



In some instances the reaction of (II) with (III) first yields an intermediate of formula



which may in situ or, if desired, after isolating and further purifying it, be cyclized to the desired compounds of formula (I).


In (II) and (II-a) X^1 is O, S or NH.

- 10 W as used in the foregoing and following reaction schemes is an appropriate leaving group such as, for example, halo, e.g. chloro, bromo or iodo, a sulfonyloxy group, e.g. methylsulfonyloxy or 4-methylphenylsulfonyloxy, and where W is connected to a $-C(=X^1)-$, $-C(=X^1)-$ or $-C(=X^2)-$ radical it may also be C_{1-6} alkyloxy, C_{1-6} alkylthio, 15 Ar^2-O- , or Ar^2-S- .

The piperidine of formula (II) may in situ be generated, for example, by converting a piperidine which is substituted in its 4-position with a $-B-C(=X^1)-OH$ radical into a piperidine of formula (II) by reacting the former piperidine with thionyl chloride, phosphor 20 trichloride, phosphoryl chloride, polyphosphoric acid, phosphoroxo chloride and the like.


The reaction of (II) with (III) may be conducted in a suitable solvent such as, for example, a hydrocarbon, e.g., benzene, hexane; an ether, e.g., 1,1'-oxybisethane, tetrahydrofuran; a ketone, e.g., 2-propanone, 25 2-butanone; an alcohol, e.g., methanol, ethanol, 2-propanol, 1-butanol; a halogenated hydrocarbon, e.g., trichloromethane, dichloromethane, an organic acid, e.g., acetic acid, propanoic acid; a polar aprotic solvent e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like; and mixtures of such solvents. Depending upon 30 the solvent and nature of W it may be appropriate to add an appropriate base and/or a iodide salt, preferably an alkali metal iodide, to the reaction mixture. Elevated temperatures may enhance the reaction rate.

The compounds of formula (I) can also be prepared by reacting an intermediate of formula (V) with a piperidine of formula (IV) wherein E^1 and E^2 are selected so that during the reaction a radical -B- is formed.




For example, the compounds of formula (I) can be prepared by reacting a piperidine of formula (IV) wherein E^1 is a radical of formula -B-M with an intermediate of formula (V) wherein E^2 is a radical of

15 formula -W.




In (IV-a) M is, depending upon the nature of B, hydrogen or an appropriate alkali metal or earth alkaline metal and in (V-a) W has the

25 previously described meaning. Additionally, the compounds of formula (I) can also be prepared by reacting a piperidine of formula (IV) wherein E^1 is W with an intermediate of formula (V) wherein E^2 is a radical of formula -B-M, said W and M having the previously described meanings.




More particularly, the compounds of formula (I) wherein B is $-\text{CH}_2-$ can also be prepared by reacting a piperidine of formula (IV) wherein E^1 represents a radical of formula $-\text{CH}_2-\text{W}$, (IV-c), with an intermediate of formula (V) wherein E^2 represents M, (V-c) or alternatively, by reacting a piperidine of formula IV, wherein E^1 is a radical of formula $-\text{M}$, (IV-d), with an intermediate of formula (V) wherein E^2 is a radical of formula $-\text{CH}_2-\text{W}$, (V-d).



The reaction of (IV) with (V) may conveniently be conducted in an appropriate solvent such as for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene; an ether, e.g. 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran and the like; a halogenated hydrocarbon, e.g. trichloromethane and the like; N,N-dimethylformamide (DMF); N,N-dimethylacetamide (DMA); and where M is hydrogen, said solvent may also be a C_{1-6} alkanol, e.g., methanol, ethanol, 1-butanol and the like; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone and the like. In some circumstances, the addition of an appropriate base such as, for example, an alkali metal carbonate or hydrogen carbonate, sodium hydride or an organic base such as, for example, N,N-diethylethanamine or N-(1-methylethyl)-2-propanamine and/or the addition of a iodide salt, preferably an alkali metal iodide, may be appropriate. Somewhat elevated temperatures may enhance the rate of the reaction.


The compounds of formula (I), wherein B is NR, can also be prepared by a cyclodesulfurization reaction of an appropriate thiourea derivative of formula



10 Said cyclodesulfurization reaction may be carried out by the reaction of (VI-a) with an appropriate alkyl halide, preferably iodomethane in an appropriate reaction-inert organic solvent, e.g., a C₁₋₆ alkanol such as methanol, ethanol, 2-propanol and the like. Otherwise, the cyclodesulfurization reaction may be carried out by the
 15 reaction of (VI-a) with an appropriate metal oxide or salt in an appropriate solvent according to art-known procedures. For example, the compounds of formula (I) can easily be prepared by the reaction of (VI-a) with an appropriate Hg(II) or Pb(II) oxide or salt, such as, for example HgO, HgCl₂, Hg(OAc)₂, PbO or
 20 Pb(OAc)₂. In certain instances it may be appropriate to supplement the reaction mixture with a small amount of sulfur. Even so methanediimines, especially N,N'-methanetetraylbis[cyclohexanamine] may be used as cyclodesulfurizing agents.

In some instances compounds of formula (I), wherein B is NR, may
 25 alternatively be prepared by cyclodesulfurizing a thiourea of formula (VI-b) and subsequently dehydrating the thus obtained oxazole[5,4-d]pyrimidine derivatives with a suitable dehydrating agent, e.g., phosphoryl chloride, phosphor trichloride, phosphor pentachloride, thionyl chloride and the like.

30




35

In (VI-b) R^{1-a} has the same meaning as described hereinabove for R^1 .

The compounds of formula (I) can also be converted into each other. A number of such reactions will be described hereinafter in more detail.


In order to simplify the structural representations of the compounds of formula (I) and of certain precursors and intermediates thereof the



-radical will hereafter be

represented by the symbol D.

The compounds of formula (I) wherein L is L^2 , said compounds being represented by the formula (I-b) can be prepared by alkylating an intermediate of formula (VII) with a compound of formula (I) wherein L is Q^2 , said compound being represented by the formula (I-c).




L^2 as defined hereinabove is a radical of formula (b-1) other than hydrogen, said radical being represented by the formula (b-1-a), or a radical of formula (b-2).

In (VII) and (I-c), Q^1 and Q^2 are selected so that a bivalent radical of formula (b-1-a) or (b-2) is formed during the alkylation reaction, said (b-1-a) and (b-2) having the previously described meaning.



For example, the compounds of formula (I-b) can be prepared by N-alkylating a piperidine of formula (I-c) wherein Q^2 is hydrogen, said piperidine being represented by the formula (I-c-1),

5




In some instances the alkylating reagent (VII-a) can also be a reactive cyclic reagent which may be formed by an intramolecular cyclisation reaction. The said cyclic form of (VII-a) may be formed in situ, or if desired, isolated and further purified before reacting it with (I-c-1).

Additionally, the compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a), wherein T is T^2 , said T^2 being O, S, NR^3 or $-Z^1-C(=X)-Y-$, said Z^1 being O, S or NR^5 , or a radical of formula (b-2) wherein T^1 is T^3 , said T^3 being $-Z^1-C(=X)-$ or a direct bond, said compounds being represented by the formulae (I-b-1-a), respectively (I-b-1-b), can be prepared by alkylating a piperidine of formula (I-c-2) with a reagent of formula (VII-b).



In (I-c-2) Q^{2a} is a radical of formula $HT^2-C_{s_2s}-$,


30 respectively a radical of formula HT³-

and W^1 has the previously defined meaning of W , and where $r = 0$, and L^1 is Het or Ar^1 , it may also be C_{1-6} alkyloxy or C_{1-6} alkylthio.

The compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a), wherein T is T^4 , said T^4 being O, S, NR^3 or $-Z-C(=X)-Y^1-$, said Y^1 being O, S or NR^3 , and said compounds

- being represented by the formula (I-b-2), may also be prepared by
 5 alkylating a piperidine of formula (I-c) wherein Q^2 is a radical of formula $-C_{s2s}H_{2s}-W$, said piperidine being represented by the formula (I-c-3), with a reagent of formula (VII) wherein Q^1 is a radical of formula $-C_{r2r}H_{2r}-T^4H$, said reagent being represented by the formula (VII-c).

10




- The alkylation reactions are conveniently conducted in an inert
 15 organic solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene, and the like; a C_{1-6} alcohol, e.g., methanol, ethanol, 1-butanol and the like; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone and the like; an ether, e.g., 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran and the
 20 like; N,N-dimethylformamide (DMF); N,N-dimethylacetamide (DMA); dimethyl sulfoxide (DMSO); nitrobenzene; 1-methyl-2-pyrrolidinone; and the like. The addition of an appropriate base such as, for example, an alkali metal carbonate or hydrogen carbonate, sodium hydride or an organic base such as, for example, N,N-diethylethanamine or
 25 N-(1-methylethyl)-2-propanamine may be utilized to pick up the acid which is liberated during the course of the reaction. In some circumstances the addition of a iodide salt, preferably an alkali metal iodide, is appropriate. Somewhat elevated temperatures may enhance the rate of the reaction.

30


The compounds of formula (I-b) can also be prepared by the reductive N-alkylation reaction of (I-c-1) with an appropriate carbonyl-compound of formula $L^{2-a}=C=O$ (VIII), said $L^{2-a}=C=O$ being a compound of formula L^2-H wherein a $-CH_2-$ radical is oxidated to a carbonyl radical.

35






hydrogen atmosphere and in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products
 5 it may be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene and the like.

The compounds of formula (I-b), wherein L is a radical of formula (b-1-a) wherein T is $Z^1-C(=X^2)-NH-$, Z^1 being as previously described, X^2 being O or S, and said compounds being represented by
 10 the formula (I-b-4), can generally be prepared by reacting an isocyanate or isothiocyanate of formula (I-f) with a reagent of formula (XI):






The compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a), wherein T is $-NH-C(=X^2)-Y^1-$, Y^1 being as
 20 previously described, and the compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a), wherein T is $-NH-C(=X^2)-$ and s is 0, and the compounds of formula (I-b), wherein L^2 is a radical of formula (b-2), wherein T^1 is $-NH-C(=X^2)-$, said compounds being represented by the formula (I-b-5-a), respectively (I-b-5-b) and
 25 (I-b-5-c), can be prepared by reacting an isocyanate or isothiocyanate of formula (XII) with a piperidine of formula (I-c-4), respectively (I-c-1) and (I-c-5).





The reaction of (XI) with (I-f) and of (XII) with (I-c-4), respectively (I-c-1) and (I-c-5) may be conducted in a suitable reaction-inert solvent such as, for example, a hydrocarbon, e.g., benzene, a ketone, e.g., acetone, a halogenated hydrocarbon, e.g., dichloromethane, trichloromethane, an ether, e.g., 1,1'-oxybisethane, tetrahydrofuran and the like. Elevated temperatures may be suitable to enhance the rate of the reaction.

15 The compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a), wherein T is $-\text{C}(=\text{X}^2)-\text{Y}^1-$, and the compounds of formula (I-b), wherein L is a radical of formula (b-1-a), wherein s is 0 and T is a radical of formula $-\text{C}(=\text{X}^2)-$, and the compounds of formula (I-b) wherein L^2 is a radical of formula (b-2), wherein T^1 is $-\text{C}(=\text{X}^2)-$, said compounds being represented by the formula (I-b-6-a), respectively (I-b-6-b) and (I-b-6-c), may be prepared by reacting a piperidine of formula (I-c-4), respectively (I-c-1) and (I-c-5) with a reagent of formula (XIII).




The reaction of (XIII) with (I-c-4), respectively (I-c-1) and (I-c-5) may generally be conducted following art-known esterification- or amidation reaction-procedures. For example, the carboxylic acid may be converted into a reactive derivative, e.g., an anhydride or a carboxylic acid halide, which subsequently, is reacted with (I-c-4), (I-c-1) or (I-c-5); or by reacting (XIII) and (I-c-4), respectively (I-c-1) and (I-c-5) with a suitable reagent capable of forming amides or esters, e.g., dicyclohexylcarbodiimide, 2-chloro-1-methylpyridinium iodide and the like. Said reactions are most conveniently conducted in a suitable solvent such as, for example, an ether, e.g. tetrahydrofuran, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane or a polar aprotic solvent, e.g. N,N-dimethylformamide. The addition of a base, e.g. N,N-diethylethanamine may be appropriate.


15

The compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a) wherein T is $-Z^1-C(=X)-Y^1-$, and the compounds of formula (I-b), wherein L^2 is a radical of formula (b-1-a) wherein s is 0 and T is $-Z^1-C(=X)-$, and the compounds of formula (I-b), wherein L^2 is a radical of formula (b-2) wherein T¹ is $-Z^1-C(=X)-$, said compounds being represented by the formula (I-b-7-a), respectively (I-b-7-b) and (I-b-7-c), can also be prepared by reacting (XI) with (I-c-4), respectively (I-c-1) and (I-c-5) in the presence of an appropriate >C=X generating agent.


25



30




35



5


An appropriate $\text{C}=\text{X}$ generating agent is, for example, 1,1'-thiocarbonylbis[1H-imidazole], 1,1'-carbonylbis[1H-imidazole], carbonic dichloride, carbonothioic dichloride, urea, thiourea, trichloroacetyl chloride, and the like. The reaction of (XI) with (I-c-4), (I-c-1) or (I-c-5) is conveniently conducted in a suitable solvent, such as, for example, a hydrocarbon, e.g., benzene, methylbenzene; an ether, e.g., 1,1'-oxybisethane, tetrahydrofuran; a halogenated hydrocarbon, e.g., dichloromethane, trichloromethane and the like. The addition of a base such as, for example, an alkali metal carbonate or hydrogen carbonate or an organic base, e.g., N,N-diethylethanamine and the like, may be appropriate.

The compounds of formula (I-b) wherein L^2 is a radical of formula (b-1), wherein s is an integer of from 2 to 6 inclusive, said
20 compounds being represented by the formula (I-g) can be prepared by reacting an appropriate alkene of formula (XIV) with a piperidine of formula (I-c-1).



The compounds of formula (I-b) wherein L^2 is a radical of formula $L^1-C_{r'}H_{2r'}-T-C_{s'}H_{2s'}-CH(Y^1H)-CH_2-$, wherein s' is an integer of from 2 to 6 inclusive, said compounds being represented by the formula (I-h)

30 may also be prepared by reacting a reagent of formula (XV) with a piperidine of formula (I-c-1).



5

(XV)

(I-h)



The reactions of (XIV) with (I-c-1), and (XV) with (I-c-1) may be conducted by stirring and, if desired, heating the reactants together. The said reactions may be conducted in a suitable solvent such as, for example, an alkanone, e.g. 2-propanone, 4-methyl-2-propanone, an ether, e.g. tetrahydrofuran, 1,1'-oxybisethane, an alcohol, e.g. methanol, ethanol, 1-butanol, N,N-dimethylformamide, N,N-dimethylacetamide and the like.

It is evident that the radical " $-C_{2-6}$ alkenyl-", the corresponding " $-C_{2-6}$ alkanediyl-" radical and the radical $C_{2s'-2}H_{2s'-4}$ may bear the previously described substitutions of the radical $-C_sH_{2s}-$.

The compounds of formula (I) wherein L^1 is Het, said compounds being represented by the formula (I-i), may also be prepared following procedures for preparing ring systems which are known in the art or analogous procedures thereof. A number of such cyclization procedures will be described hereinafter.


The bivalent radical K used in the description of these cyclization reactions has the following meaning:

25



30


and the radicals (e-1-a), (e-2), (e-3), (e-5-a), (e-6), (e-7) and (e-8) also used in the description of these cyclization reactions have the following meaning :



20 X^2 , R^{11} , R^{13} , R^{14} , R^{15} , R^{16} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} , G^1 , G^3 , G^4 , G^5 and G^6 have the same meaning as defined hereinabove for the particularly preferred compounds.

For example, the compounds of formula (I-1) wherein Het is an optionally substituted imidazolyl radical, said compounds being represented by the formula (I-1-1), can be prepared by the cyclization reaction of an appropriate N -(2,2-diC₁₋₆ alkyloxyethyl)imidamide derivative of formula (XVI).



25



wherein R^{25} , R^{26} and R^{27} are each independently optional substituents of the imidazole ring.


5 Said cyclization reaction may conveniently be conducted in a suitable solvent in the presence of an appropriate acid such as, for example, hydrochloric, hydrobromic and the like acids. Elevated temperatures may enhance the rate of the reaction.

10 The compounds of formula (I-1) wherein Het is an optionally substituted thiazolyl radical, being optionally condensed with a five- or six-membered hetero- or carbocyclic ring, may be prepared by a number of cyclization reactions, yielding, depending upon the case, compounds which may be represented by the formula (I-1-2) or (I-1-3).




R^{28} , R^{29} , R^{30} and R^{31} are each independently optional substituents of the said thiazolyl ring, or, where in the compounds of formula (I-1-2) said thiazolyl ring is condensed with a five- or six-membered hetero- or carbocyclic ring, R^{28} and R^{29} taken together may form a bivalent radical of formula G^4 .


30 Further, where Het is a radical of formula (e-1-a), said Het may be formed by condensing an intermediate (XXI) with a $>C=X^2$ generating agent, e.g. urea, thiourea, 1,1'-carbonylbis[1H-imidazole], C_{1-6} alkyl carbonohalidate, phosgene, thiophosgene, trichloromethyl carbonohalidate and the like.



The compounds of formula (I-i-4) wherein R¹¹ is hydrogen may additionally be prepared by cyclizing an intermediate of formula



15 reacting a reagent (XXIII) with an amine (XXIV).




The reaction of (XXI) with the >C=X^2 generating agent and the cyclization of (XXII) may conveniently be conducted in a suitable solvent such as, for example, an ether, e.g. 1,1-oxybisethane, tetrahydrofuran, an halogenated hydrocarbon, e.g. dichloromethane, trichloromethane, a hydrocarbon, e.g. benzene, methylbenzene, an alcohol, e.g. methanol, ethanol, a ketone, e.g. 2-propanone, 4-methyl-2-pentanone, N,N-dimethylformamide, N,N-dimethylacetamide, or mixtures of such solvents, optionally in the presence of an appropriate base such as, for example, N,N-diethylethanamine, an alkali or earth alkaline metal carbonate or hydrogen carbonate. In order to enhance the reaction rate, it may be suitable to heat the reaction mixture.

Further, where Het is a radical of formula (e-2), said Het may be generated by cyclizing an intermediate (XXV) with an acid (XXVI) or a

suitable functional derivative thereof, thus preparing a compound of formula (I-i-5). Alternatively an intermediate (XXVII) may be condensed with an aromatic amino acid or -thioacid of formula (XXVIII), preparing also a compound (I-i-5).

5




15

The reaction of (XXV) with (XXVI) and of (XXVII) with (XXVIII) may be conducted in a suitable reaction-inert solvent, such as, for example, a hydrocarbon, e.g. benzene, methylbenzene, an alcohol, water. In some instances it may be appropriate to use higher temperatures in order to reduce the reaction time.


Where Het is a radical of formula (e-3), wherein R¹⁶ is hydrogen and R¹⁵ is a radical of formula R^{15-a}-CH₂-, said Het may be formed by reacting a compound (XXIX) with an appropriate acetylene derivative (XXX), thus preparing a compound of formula (I-i-6).

25 Additionally, where Het is a radical of formula (e-3), said Het may be formed by reacting (XXIX) with a ketone of formula (XXXI), thus preparing a compound of formula (I-i-7).




35

5




The reaction of (XXIX) with (XXX) may be conducted in a suitable solvent such as, for example, an alcohol, e.g. methanol, ethanol, while the reaction of (XXIX) with (XXXI) may be conducted in a suitable solvent preferably in the presence of an organic acid such as, for example, ethanedioic acid and the like. Elevated temperatures may also be appropriate to shorten the reaction time.


Additionally, where Het is a radical (e-5-a), said Het may be created by condensing a reagent (XXXII) with an intermediate (XXXIII), thus giving a compound (I-i-8).



Where Het is a radical (e-6) being connected to K by the G^4 containing ring and bearing a 2-mercaptosubstituent, said Het may be formed during the cyclization of an intermediate (XXXIV) with CS_2 , thus preparing a compound (I-i-9).




Where Het is a radical of formula (e-7) being connected to K either by the G^5 containing ring or by the imidazole ring, said Het is formed during the condensation reaction of a reagent (XXXV) with an intermediate (XXXVI) respectively by the cyclodesulfurization reaction of an intermediate (XXXVII), thus preparing a compound (I-i-10) respectively (I-i-11).



- The reactions of (XXXII) with (XXXIII), of (XXXIV) with CS_2 and (XXXV) with (XXXVI) may conveniently be conducted in a suitable reaction-inert solvent, such as for example one of the solvents given hereinabove for the preparation of (I-i-4) optionally in the presence of an appropriate base, e.g. one of the bases also described for the preparation of (I-i-4); higher temperatures may be used to enhance the reaction rate.
- 20 The cyclodesulfurization of (XXXVII) may be carried out by the reaction of (XXXVII) with an appropriate alkyl halide, preferably iodomethane in an appropriate reaction-inert organic solvent, e.g., a C_{1-6} alkanol such as methanol, ethanol, 2-propanol and the like. Otherwise, the cyclodesulfurization reaction may be carried out by the
- 25 reaction of (XXXVII) with an appropriate metal oxide or salt in an appropriate solvent according to art-known procedures. For example, the compounds of formula (I) can easily be prepared by the reaction of (XXXVII) with an appropriate Hg(II) or Pb(II) oxide or salt, such as, for example HgO , HgCl_2 , Hg(OAc)_2 , PbO or Pb(OAc)_2 . In certain
- 30 instances it may be appropriate to supplement the reaction mixture with a small amount of sulfur. Even so methanediimines, especially N,N' -methanetetraylbis[cyclohexanamine] may be used as cyclodesulfurizing agents.

Where Het is a radical (e-8), said Het may be formed during the condensation of an intermediate (XXXVIII) with a >C=X^2 generating agent, following the same procedures as previously described for the preparation of (I-i-4) starting from (XXXIII).

5



10

The compounds of formula (I) can also be converted into each other following art-known procedures of functional grouptrans-formation. Some examples will be cited hereinafter.

The compounds of formula (I), wherein -B- is -S- may be converted
 15 into the corresponding compounds of formula (I), wherein -B- is -SO- or -SO₂- by an appropriate oxidation reaction, e.g. by reacting the former compounds with a suitable oxidating agent such as, for example, potassium periodate, a peroxide, e.g. 3-chlorobenzenecarboxperoxyic acid, hydrogen peroxide, and the like, in a suitable solvent such as,
 20 for example, an ether, e.g. tetrahydrofuran, 1,1'-oxybisethane, a hydrocarbon, e.g. benzene, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like. In the instance where a sulfinyl is desired, said oxidation reaction is preferably conducted at lower temperatures with approximately one equivalent of the
 25 oxidating agent, while where a sulfonyl is desired, said oxidation reaction may be conducted at room or elevated temperature with an excess of oxidating agent.

The compounds of formula (I) having a nitro substituent can be converted into the corresponding amines by stirring and, if
 30 desired, heating the starting nitro-compounds in a hydrogen-containing medium in the presence of a suitable amount of an appropriate catalyst such as, for example, platinum-on-charcoal, palladium-on-charcoal, Raney-nickel and the like catalysts. Suitable solvents are, for example, alcohols, e.g., methanol, ethanol
 35 and the like.

methods for preparing N-H groups such as, for example :

1. where said nitrogen is substituted with an $\text{Ar}^2\text{-CH}_2$ group, by treating the starting compounds with hydrogen in the presence of a suitable catalyst, e.g. palladium-on-charcoal, platinum-on-charcoal, in an appropriate solvent;
2. or, where said nitrogen is substituted with a sulfonyl group, e.g. C_{1-6} alkylsulfonyl and Ar^2 -sulfonyl, by treating the starting compounds with an aqueous acidic solution preferably in the presence of a catalyst such as, for example, phenol, methoxybenzene and the like;
3. or, where said nitrogen atoms are substituted with an Ar^2 -carbonyl group by treating the starting compounds with an aqueous basic solution, e.g. an alkali metal hydroxide solution;
4. where said nitrogen is substituted with C_{1-6} alkyloxy carbonyl or Ar^2 -oxycarbonyl, by treating the starting compounds with an aqueous acidic or aqueous basic solution optionally in admixture with an organic solvent or where said nitrogen atom is substituted with Ar^2 -oxycarbonyl, by catalytically hydrogenating the starting materials in a suitable solvent.

- 20 The compounds of formula (I) containing a nitrogen atom substituted with $\text{Ar}^2\text{-CH}_2$ may be converted into the corresponding compounds where said nitrogen is substituted with C_{1-6} alkyloxycarbonyl, for example by treating the former compounds with a C_{1-6} alkyl carbonohalide in the presence of a suitable solvent and, if desired, in the presence of an appropriate base.

The compounds of formula (I) containing a mercapto group may be converted into the corresponding isothiocyanato containing compounds by treating the starting amino compounds with CS_2 in the presence of N,N' -methanetetraylbis[cyclohexanamine].

- 30 The compounds of formula (I) containing a $\text{-CH}_2\text{-C(=O)-}$ fragment can be converted into the corresponding compounds of formula (I) containing a -CH(halo)-C(=O)- fragment following art-known halogenating procedures, e.g. by treating the starting compound with a halogen.


In all of the foregoing and in the following preparations, the reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art.

5 The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active non-toxic acid addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric
10 acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic,
15 methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.


20 Some intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds and others are new. A number of such preparation methods will be described hereinafter in more detail.

25 The intermediates of formula (II), wherein B is CH_2 , X^1 is NH and W is C_{1-6} alkyloxy, said intermediates being represented by the formula (II-c), can be prepared by reacting a (cyanomethyl)piperidine of formula (XXXIX) with an alcohol, e.g. methanol, ethanol and the like, in the presence of an acid, e.g. hydrochloric acid.

30



35



5 The intermediates of formula (IV) may be prepared by a reduction reaction of an appropriate 4-piperidinone, and, if desired, followed by an appropriate art-known groupstransformation procedure, e.g., where a compound of formula (V-b) is desired, by reacting the thus obtained alcohol with thionyl chloride, methanesulfonyl chloride and
10 the like in order to obtain an appropriate leaving group.

 The intermediates of formula (VI-a) can be prepared by the procedures described in, for example, European Patent Publication Nos. 0,099,139; 0,145,037 and 0,144,101.

 The intermediates of formula (VII) can conveniently be prepared
15 following art-known procedures as described in, for example, U.S. Patent Number 4,335,127, U.S. Patent Number 4,342,870 and European Patent Publication Number 0,070,053.

 From formula (I) it is evident that the compounds of this invention may have several asymmetric carbon atoms in their structure.
20 Each of these chiral centers may be present in a R- and a S-configuration, this R- and S-notation being in correspondence with the rules described by R.S. Cahn, C. Ingold and V. Prelog in Angew. Chem., Int. Ed. Engl., 5, 385, 511 (1966).

 Pure stereochemically isomeric forms of the compounds of formula
25 (I) may be obtained by the application of art-known procedures. Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g., counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric
30 salts with optically active acids.

 Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.

It is evident that the cis and trans diastereomeric racemates may be further resolved into their optical isomers, cis(+), cis(-), trans(+) and trans(-) by the application of methodologies known to those skilled in the art.

- 5 Stereochemically isomeric forms of the compounds of formula (I) are naturally intended to be embraced within the scope of the invention.

The compounds of the present invention possess useful pharmacological properties and are active as antihistamines and as
10 serotonin-antagonists. This is clearly demonstrated by the results of the "Protection of rats from compound 48/80-induced lethality" test.

In view of their antihistaminic properties, the compounds of formula (I) and their acid-addition salts are very useful in the
15 treatment of allergic diseases such as, for example, allergic rhinitis, allergic conjunctivities, chronic urticaria, allergic asthma and the like.

In view of their useful pharmacological properties the subject compounds may be formulated into various pharmaceutical forms for
20 administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form
25 of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be
30 employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of
35 their ease in administration, tablets and capsules represent the most

advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The present invention is also related with a method of treating allergic diseases in warm-blooded animals suffering from said allergic diseases by administering an effective anti-allergic amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.

Those of skill in treating allergic diseases in warm-blooded animals could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective amount would be from 0.1 mg to 100 mg, more preferably from 1 to 50 mg.

The following examples are intended to illustrate and not to limit the scope of the present invention in all its aspects. Unless otherwise stated all parts therein are by weight.

15

20

25

30

35

EXPERIMENTAL PARTA. Preparation of IntermediatesExample 1

A mixture of 3.7 parts of 2-pyridinemethanamine, 4.1 parts of
5 4,6-dichloropyrimidin-5-amine, 3.03 parts of N,N-diethylethanamine
and 150 parts of water was stirred for 8 hours at room temperature.
After cooling, the whole was stirred overnight. The product was
filtered off, washed with water and dried overnight in vacuo at
80°C, yielding 5.35 parts (90.8%) of 6-chloro-N⁴-(2-pyridinyl-
10 methyl)-4,5-pyrimidinediamine; mp. 140.3°C (interm. 1).

In a similar manner there were also prepared:

- 6-chloro-N⁴-[(4-fluorophenyl)methyl]-4,5-pyrimidinediamine;
mp. 244.4°C (interm. 2);
6-chloro-N⁴-(2-furanylmethyl)-4,5-pyrimidinediamine mp. 138.7°C
15 (interm. 3);
6-chloro-N⁴-(2-thienylmethyl)-4,5-pyrimidinediamine; mp. 165.5°C
(interm. 4);
6-chloro-N⁴-[(5-methyl-2-furanyl)methyl]-4,5-pyrimidinediamine
(interm. 5);
20 6-chloro-N⁴-(2-pyrazinylmethyl)-4,5-pyrimidinediamine (interm. 6);
6-chloro-N⁴-(4-thiazolylmethyl)-4,5-pyrimidinediamine; mp. 145.5°C
(interm. 7);
6-chloro-N⁴-[(4-methoxyphenyl)methyl]-4,5-pyrimidinediamine;
mp. 183.5°C (interm. 8); and
25 N⁴-[(4-fluorophenyl)methyl]-6-methyl-4,5-pyrimidinediamine;
(interm. 9).

In a similar manner there is also prepared:

- 6-chloro-N⁴-[(2,4-dimethylphenyl)methyl]-4,5-pyrimidinediamine;
(interm. 10).

30 Example 2

To a stirred mixture of 20.2 parts of 4,5-pyrimidinediamine, 40
parts of pyridine and 144 parts of N,N-dimethylformamide was added
dropwise a solution of 24.2 parts of 4-fluorobenzoyl chloride in 36
parts of N,N-dimethylformamide at 10°C. Upon completion, stirring
35 was continued for 30 minutes at room temperature. 600 Parts of water

were added. The product was filtered off and dried, yielding 30 parts (70%) of N-(4-amino-5-pyrimidinyl)-4-fluorobenzamide (interm. 11).

To a stirred mixture of 30 parts of N-(4-amino-5-pyrimidinyl)-4-fluorobenzamide and 360 parts of tetrahydrofuran were added portionwise 9.86 parts of lithium tetrahydroaluminate under nitrogen atmosphere. The mixture was stirred for 6 hours. Another portion of 10 parts of lithium tetrahydroaluminate was added portionwise and stirring was continued for 2 hours at room temperature. The reaction mixture was decomposed with water. The layers were separated. The aqueous phase was extracted with tetrahydrofuran. The combined organic layers were dried, filtered and evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 18 parts (63.5%) of N⁵-[(4-fluorophenyl)methyl]-4,5-pyrimidinediamine (interm. 12).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

N-(4-amino-6-hydroxy-5-pyrimidinyl)-4-fluorobenzamide (interm. 13); and

6-amino-5-[[(4-fluorophenyl)methyl]amino]-4-pyrimidinol (interm. 14).

Example 3

A mixture of 62.2 parts of 6-chloro-N⁴-(2-pyridinylmethyl)-4,5-pyrimidinediamine, 3 parts of a solution of thiophene in methanol 4%, 20 parts of calcium oxide and 400 parts of methanol was hydrogenated at normal pressure and at 50°C with 5 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 63.5 parts (100%) of N⁴-(2-pyridinylmethyl)-4,5-pyrimidinediamine as a residue (interm. 15).

In a similar manner there were also prepared:

N⁴-[(4-fluorophenyl)methyl]-4,5-pyrimidinediamine as a residue (interm. 16);

N⁴-(2-furanylmethyl)-4,5-pyrimidinediamine; mp. 116.4°C (interm. 17);

N⁴-(2-thienylmethyl)-4,5-pyrimidinediamine (interm. 18);

N^4 -[(5-methyl-2-furanyl)methyl]-4,5-pyrimidinediamine (interm. 19);
 N^4 -(2-pyrazinylmethyl)-4,5-pyrimidinediamine as a residue
(interm. 20);

N^4 -[(4-methoxyphenyl)methyl]-4,5-pyrimidinediamine (interm. 21);

5 and

N^4 -(4-thiazolylmethyl)-4,5-pyrimidinediamine (interm. 22).

In a similar manner there is also prepared:

N^4 -[(2,4-dimethylphenyl)methyl]-4,5-pyrimidinediamine (interm. 23).

Example 4

10 A mixture of 8.72 parts of N^4 -[(4-fluorophenyl)methyl]-
4,5-pyrimidinediamine, 63 parts of carbon disulfide and 45 parts of
 N,N -dimethylformamide was stirred for 3 hours at reflux temperature.
After cooling, the reaction mixture was poured into water. The
precipitated product was filtered off and dried, yielding 10.1 parts
15 (78.9%) of 9-[(4-fluorophenyl)methyl]-9H-purine-8-thiol (interm. 24).

To a stirred mixture of 4.6 parts of potassium hydroxide and 200
parts of water were added portionwise 1.7 parts of iodomethane,
followed by the dropwise addition of 3.8 parts of 9-[(4-fluoro-
phenyl)methyl]-9H-purine-8-thiol. Upon complete addition, the whole
20 was stirred for 2 hours at room temperature. The precipitated
product was filtered off and dried, yielding 3.45 parts (73.9%) of
9-[(4-fluorophenyl)methyl]-8-(methylthio)-9H-purine; mp. 167.1°C
(interm. 25).

Example 5

25 A mixture of 26 parts of methyl 3-methyl-4-oxo-1-piperidine-
carboxylate, 16.5 parts of benzenemethanamine, 2 parts of a solution
of thiophene in ethanol 4% and 200 parts of methanol was
hydrogenated at normal pressure and at room temperature with 3 parts
of palladium-on-charcoal catalyst 10%. After the calculated amount
30 of hydrogen was taken up, the catalyst was filtered off and the
filtrate was evaporated to dry, yielding 40.2 parts of methyl
3-methyl-4-[(phenylmethyl)amino]-1-piperidinecarboxylate as a
residue (interm. 26).

A mixture of 40 parts of methyl 3-methyl-4-[(phenylmethyl)-
35 amino]-1-piperidinecarboxylate and 160 parts of methanol was

hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated to dry. The residue was distilled (bp. 80°C at 0.1 mm. pressure). The distillate was further purified by

5 gas-chromatography (at 215°C and at 10 lbs/sq. inch), yielding 8.6 parts of methyl 4-amino-3-methyl-1-piperidinecarboxylate (interm. 27)

To a stirred and cooled (-10°C) mixture of 138.6 parts of carbon disulfide, 113.8 parts of N,N'-methanetetraylbis[cyclohexanamine],

10 and 450 parts of tetrahydrofuran were added dropwise 106 parts of methyl 4-amino-3-methyl-1-piperidinecarboxylate at this low temperature. The reaction mixture was allowed to attain room temperature. After stirring for 1 hour at room temperature, the mixture was evaporated and the residue was stirred in 2,2'-oxybis-

15 propane. The precipitate was filtered off and the filtrate was evaporated, yielding 141.1 parts (100%) of methyl cis-4-isothiocyanato-3-methyl-1-piperidinecarboxylate as a residue (interm. 28).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:


20 methyl (cis+trans)-methyl 4-amino-3-methyl-1-piperidinecarboxylate; bp. 136-140°C (water-jet) (interm. 29); and methyl (cis+trans)-4-isothiocyanato-3-methyl-1-piperidinecarboxylate as a residue (interm. 30).

Example 6

25 A mixture of 42.5 parts of N⁴-(2-furanylmethyl)-4,5-pyrimidinediamine, 50.5 parts of ethyl 4-isothiocyanato-1-piperidinecarboxylate and 630 parts of tetrahydrofuran was stirred for 48 hours at reflux temperature. After cooling, the product was filtered off, washed with tetrahydrofuran and 1,1'-oxybisethane and dried,

30 yielding 86.4 parts (96.2%) of ethyl 4-[[[4-[(2-furanylmethyl)-amino]-5-pyrimidinyl]amino]thioxomethyl]-amino]-1-piperidinecarboxylate (interm. 31).

In a similar manner there were also prepared:



No.	L	R ²	R ¹	-A ¹ =A ² -A ³ =A ⁴ -	isomeric form	mp. °C
10	32	C ₂ H ₅ OCO-	H	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	-
	33	C ₂ H ₅ OCO-	H	2-thienyl-CH ₂ -	-N=C-N=C-	-
	34	C ₂ H ₅ OCO-	H	2-pyridinyl-CH ₂ -	-N=C-N=C-	-
	35	C ₆ H ₅ CH ₂ -	H	4-F-C ₆ H ₄ -CH ₂ -	-C=N-C=N-	-
	36	C ₂ H ₅ OCO-	H	(5-CH ₃ -2-furanyl)-CH ₂ -	-N=C-N=C-	-
15	37	C ₂ H ₅ OCO-	H	2-pyrazinyl-CH ₂ -	-N=C-N=C-	-
	38	CH ₃ OCO-	3-CH ₃	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	cis
	39	CH ₃ OCO-	3-CH ₃	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	cis+trans
	40	C ₂ H ₅ OCO-	H	4-CH ₃ O-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	-
20	41	C ₂ H ₅ OCO-	H	4-thiazolyl-CH ₂ -	-N=C-N=C-	-

In a similar manner there were also prepared:

N-(4-amino-6-hydroxy-5-pyrimidinyl)-N'-[(4-fluorophenyl)methyl]-N'-[1-(phenylmethyl)-4-piperidinyl]thiourea; mp. 192.9°C (interm. 42);

25 and

ethyl 4-[[[(4-amino-6-hydroxy-5-pyrimidinyl)[(4-fluorophenyl)-methyl]amino]-thioxomethyl]amino]-1-piperidinecarboxylate (interm. 43).

In a similar manner there is also prepared:

30 ethyl 4-[[[4-[[[(2,4-dimethylphenyl)methyl]amino]-5-pyrimidinyl]amino]thioxomethyl]amino]-1-piperidinecarboxylate (interm. 44).

Example 7

A mixture of 52.4 parts of 1-(phenylmethyl)-4-piperidineacetic acid hydrochloride, 38.7 parts of N⁴-[(4-fluorophenyl)methyl]-

35

4,5-pyrimidinediamine and 765 parts of phosphoryl chloride was stirred and refluxed for 30 minutes. The reaction mixture was evaporated. The residue was decomposed with ice water. The product was extracted with dichloromethane after treatment with sodium hydroxide. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 37 parts (61%) of N-[4-[[4-fluorophenyl)methyl]-amino]-5-pyrimidinyl]-1-(phenylmethyl)-4-piperidineacetamide; mp. 157.3°C (interm. 45).

Example 8

To a stirred mixture of 14.2 parts of isocyanatoethane, 29.2 parts of sodium azide and 135 parts of dry tetrahydrofuran was added a solution of 39 parts of aluminum chloride in 225 parts of dry tetrahydrofuran. Stirring was continued overnight at reflux temperature. The reaction mixture was cooled and acidified with a hydrochloric acid solution 6N. The whole was evaporated to dry and the product was extracted four times with 2-propanone. The combined extracts were dried, filtered and evaporated. The residue was dried overnight, yielding 18 parts (65%) of 1-ethyl-1,4-dihydro-5H-tetrazol-5-one (interm. 46).

To a stirred solution of 109 parts of 1,2-dibromoethane and 21.2 parts of sodium carbonate in 5 parts of water and 18 parts of N,N-dimethylformamide were added dropwise a solution of 22.5 parts of 1-ethyl-1,4-dihydro-5H-tetrazol-5-one in 5 parts of water and 27 parts of N,N-dimethylformamide at about 40°C. Upon completion, stirring was continued overnight at 40°C. The organic phase was separated, dried and distilled, yielding 9.8 parts (22%) of 1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one; bp. 110°C at 0.1 mm pressure (interm. 47).

Example 9

A mixture of 50 parts of 2-thiazolamine, 76 parts of 3-acetyl-4,5-dihydro-2(3H)-furanone, 1.2 parts of concentrated hydrochloric acid and 270 parts of methylbenzene was stirred and refluxed for 2 hours using a water-separator. The reaction mixture was cooled and 340 parts of phosphoryl chloride were added at a temperature between 20 and 30°C. The whole was heated slowly to 100~110°C and stirring was continued for 2 hours at this temperature. The reaction mixture was evaporated and the residue was poured into a mixture of crushed ice and ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 1,1'-oxybisethane, yielding 36 parts of 6-(2-chloroethyl)-7-methyl-5H-thiazolo-[3,2-a]pyrimidin-5-one (interm. 48).

20 B. Preparation of Final compounds

Example 10

A mixture of 20.65 parts of 1-(phenylmethyl)-4-piperidineacetic acid hydrochloride, 19.5 parts of 6-chloro-N⁴[(4-fluorophenyl)methyl]-4,5-pyrimidinediamine and 510 parts of phosphoryl chloride was stirred and refluxed for 13 hours. The reaction mixture was evaporated. The residue was poured into ice water. The whole was treated with sodium hydroxide. The product was extracted with 4-methyl-2-pentanone. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (97:3 by volume) as eluent. The first fraction was collected and the eluent was evaporated, yielding 23.6 parts (75%) of 6-chloro-9-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]-methyl]-9H-purine as an oily residue (compound 1).

In a similar manner there was also prepared:

6-chloro-7-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]-methyl]-7H-purine (compound 2); and

9-[(4-fluorophenyl)methyl]-6-methyl-8-[[1-(phenylmethyl)-4-piperidinyl]-methyl]-9H-purine as an oily residue (compound 3).

Example 11

A mixture of 36 parts of N-[4-[(4-fluorophenyl)methyl]amino]-5-pyrimidinyl]-1-(phenylmethyl)-4-piperidineacetamide and 935 parts of phosphoryl chloride was stirred and refluxed for 8 hours. After cooling, the reaction mixture was evaporated. The residue was decomposed in ice water. The whole was treated with a sodium hydroxide solution. The product was extracted with 4-methyl-2-pentanone. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (97:3 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was stirred in 2,2'-oxybispropane. The product was filtered off and crystallized from acetonitrile. The product was filtered off and dried, yielding 10.6 parts (30.4%) of 9-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-9H-purine; mp. 136.4°C (compound 4).

Example 12

A mixture of 12.6 parts of 1-(phenylmethyl)-4-piperidinol, 3.2 parts of a sodium hydride dispersion 50% and 200 parts of N,N-dimethylacetamide was stirred for 1 hour at room temperature. Parts of 9-[(4-fluorophenyl)methyl]-8-(methylthio)-9H-purine were added portionwise and upon completion, stirring was continued for 4 hours at room temperature. The reaction mixture was poured into water. The product was filtered off and taken up in trichloromethane. The organic layer was washed with water and filtered over diatomaceous earth. The filtrate was dried, filtered and evaporated. After crystallization from acetonitrile, the product was filtered off and dried, yielding 16.75 parts (61.1%) of 9-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]oxy]-9H-purine; mp. 117.0°C (compound 5).

Example 13

To a stirred mixture of 13 parts of 9-[(4-fluorophenyl)methyl]-9H-purine-8-thiol and 300 parts of water were added 2 parts of sodium hydroxide. The reaction mixture was filtered over diatomaceous earth. After evaporation, the residue was taken up in methylbenzene and the solvent was evaporated again (this was repeated twice). The residue was taken up in 270 parts of N,N-dimethylacetamide and 19.3 parts of 1-[(4-methylphenyl)sulfonyl]-4-piperidinol methanesulfonate (ester) were added. The whole was stirred over weekend at 60°C. The reaction mixture was poured into water and the product was extracted with 4-methyl-2-pentanone. The extract was washed with water, dried, filtered and evaporated, yielding 27 parts (100%) of 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]thio]-1-[(4-methylphenyl)sulfonyl]piperidine (compound 6).

15 Example 14

A mixture of 4 parts of ethyl 4-[[[[4-[(2-furanylmethyl)amino]-5-pyrimidinyl]amino]thioxomethyl]amino]-1-piperidinecarboxylate, 6 parts of mercury(II)oxide and 80 parts of ethanol was stirred for 2 hours at reflux temperature. The whole was filtered while hot over Hyflo® and the filtrate was evaporated. The residue was crystallized from a mixture of acetonitrile and ethanol. The product was filtered off and dried, yielding 0.8 parts (21.5%) of ethyl 4-[[9-(2-furanylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate; mp. 171.9°C (compound 7).

25 Following the same procedure and using equivalent amounts of the appropriate starting materials, there was also prepared:

ethyl 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-piperidinecarboxylate; mp. 174.5°C (compound 8).

Example 15

30 A mixture of 24 parts of ethyl 4-[[[[4-[(phenylmethyl)amino]-5-pyrimidinyl]amino]thioxomethyl]amino]-1-piperidinecarboxylate, 24 parts of mercury(II) oxide and 240 parts of methanol, saturated with ammonia was stirred overnight at reflux temperature. The reaction mixture was filtered while hot and the filtrate was evaporated. The residue was taken up in a mixture of trichloromethane and ethanol.

After washing with water, the organic layer was evaporated and the residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 20.3 parts (92.1%) of ethyl 4-[[9-(phenylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate; mp. 156.9°C (compound 9).

In a similar manner there were also prepared:

- ethyl 4-[[9-(2-thienylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate as a residue (compound 10);
ethyl 4-[[9-(2-pyridinylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate (compound 11);
ethyl 4-[[9-[(5-methyl-2-furanyl)methyl]-9H-purin-8-yl]amino]-1-piperidinecarboxylate as a residue (compound 12);
ethyl 4-[[9-(2-pyrazinylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate as a residue (compound 13);
ethyl 4-[(9-methyl-9H-purin-8-yl)amino]-1-piperidinecarboxylate; mp. 169.6°C (compound 14);
ethyl 4-[[9-[(4-methoxyphenyl)methyl]-9H-purin-8-yl]amino]-1-piperidinecarboxylate; mp. 168.1°C (compound 15); and
N-[1-(phenylmethyl)-4-piperidinyl]-9H-purin-8-amine; mp. 276.1°C (compound 16).

Example 16

A mixture of 15.7 parts of ethyl 4-[[[4-(cyclopropylamino)-5-pyrimidinyl]amino]thioxomethyl]amino]-1-piperidinecarboxylate, 20 parts of mercury(II) oxide, 40 parts of ethanol and 135 parts of N,N-dimethylacetamide was stirred overnight at 80°C. The reaction mixture was filtered over diatomaceous earth while hot. The filtrate was poured into water and the product was extracted with dichloromethane. The organic layer was dried, filtered and evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 2.2 parts (14.1%) of ethyl 4-[(9-cyclopropyl-9H-purin-8-yl)amino]-1-piperidinecarboxylate; mp. 177.0°C (compound 17).

In a similar manner there was also prepared:

- ethyl 4-[[9-(4-thiazolylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate (compound 18).

Example 17

A mixture of 13 parts of methyl cis-4-[[[4-[(4-fluorophenyl)-methyl]amino]-5-pyrimidinyl]amino]thioxomethyl]amino]-3-methyl-1-piperidinecarboxylate, 13 parts of mercury(II) oxide, 0.1 parts of sulfur and 160 parts of methanol, saturated with ammonia was stirred for 0.5 hours at reflux temperature. The reaction mixture was filtered over diatomaceous earth while hot and the filtrate was evaporated. The residue was poured into water and the product was extracted with trichloromethane. The extract was washed with water, dried, filtered and evaporated. The residue was solidified in 1,1'-oxybisethane. The product was filtered off and dried, yielding 7 parts (58.5%) of methyl cis-4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-3-methyl-1-piperidinecarboxylate; mp. 152.2°C (compound 19).

In a similar manner there were also prepared:

7-[(4-fluorophenyl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]-7H-purin-8-amine; mp. 251.1°C (compound 20).

methyl (cis+trans)-4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-3-methyl-1-piperidinecarboxylate (compound 21);

In a similar manner there are also prepared:

ethyl 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]methyl-amino]-1-piperidinecarboxylate (compound 22); and

ethyl 4-[[9-[(2,4-dimethylphenyl)methyl]-9H-purin-8-yl]amino]-1-piperidinecarboxylate (compound 23).

Example 18

A mixture of 88.8 parts of ethyl 4-[[[4-amino-6-hydroxy-5-pyrimidinyl][(4-fluorophenyl)methyl]amino]thioxomethyl]amino]-1-piperidinecarboxylate, 88 parts of mercury(II) oxide, 0.1 parts of sulfur and 1200 parts of ethanol was stirred overnight at reflux temperature. The reaction mixture was filtered over diatomaceous earth while hot and the filtrate was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from ethyl acetate. The

product was filtered off and dried, yielding 50.7 parts (66.1%) of ethyl 4-[[7-amino-1-[(4-fluorophenyl)methyl]oxazolo[5,4-d]-pyrimidin-2(1H)-yliden]amino]-1-piperidinecarboxylate; mp. 174.6°C (compound 24).

- 5 A mixture of 50.7 parts of ethyl 4-[[7-amino-1-[(4-fluorophenyl)-methyl]oxazolo[5,4-d]pyrimidin-2(1H)-yliden]amino]-1-piperidine-carboxylate and 3050 parts of phosphoryl chloride was stirred for 90 minutes at reflux temperature. The reaction mixture was evaporated. The residue was poured into ice water. The whole was treated with .
- 10 ammonium hydroxide. The product was extracted with 4-methyl-2-pentanone. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure
- 15 fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 21.6 parts (41.5%) of ethyl 4-[[6-chloro-7-[(4-fluorophenyl)methyl]-7H-purin-8-yl]amino]-1-piperidinecarboxylate; mp. 126.6°C (compound 25).
- 20 Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared: 1-[(4-fluorophenyl)methyl]-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]imino]oxazolo[5,4-d]-pyrimidine-4-amine; mp. 178.5°C (compound 26); and
- 25 6-chloro-7-[(4-fluorophenyl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]-7H-purin-8-amine; mp. 248.6°C (compound 27).

Example 19

- A mixture of 16 parts of 6-chloro-7-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-7H-purine, 4.65 parts of
- 30 ethyl carbonochloridate and 180 parts of methylbenzene was stirred for 2 hours at reflux temperature. After cooling, the reaction mixture was treated with ammonium hydroxide and the product was extracted with methylbenzene. The extract was washed with water, dried, filtered and evaporated, yielding 18.7 parts (100%) of ethyl
- 35 4-[[6-chloro-7-[(4-fluorophenyl)methyl]-7H-purin-8-yl]methyl]-1-

piperidinecarboxylate as a residue (compound 28).

In a similar manner there was also prepared:

ethyl 4-[[9-[(4-fluorophenyl)methyl]-6-methyl-9H-purin-8-yl]-methyl]-1-piperidinecarboxylate (compound 29); and

5 ethyl 4-[[6-chloro-9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]-methyl]-1-piperidinecarboxylate as a residue (compound 30).

Example 20

A mixture of 24.8 parts of 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]thio]-1-[(4-methylphenyl)sulfonyl]piperidine and 300
10 parts of acetic acid, saturated with hydrogen bromide was stirred overnight at room temperature. After evaporation, the residue was taken up in water. The whole was treated with a sodium hydroxide solution and extracted with dichloromethane. The extract was acidified with a hydrochloric acid solution and extracted with
15 water. The aqueous layer was treated with a sodium hydroxide solution and the product was extracted with dichloromethane. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, (95:5 by volume) —>
20 trichloromethane and methanol, saturated with ammonia, (90:10 by volume) as eluents. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 3.0 parts (17.4%) of 9-[(4-fluorophenyl)methyl]-8-(4-piperidinylthio)-9H-purine; mp.
25 113.5°C (compound 31).

In a similar manner there is also prepared:

9-[(4-fluorophenyl)methyl]-8-(4-piperidinylsulfonyl)-9H-purine (compound 32).

Example 21

30 A mixture of 60.5 parts of ethyl 4-[[9-(2-furanylmethyl)-9H-purin-8-yl]amino]-1-piperidinecarboxylate, 90 parts of potassium hydroxide, 800 parts of 2-propanol and 20 parts of water was stirred for 48 hours at reflux temperature. The reaction mixture was evaporated. The reaction mixture was poured into water while
35 stirring. The product was filtered off and dried, yielding a first

- fraction of 36.2 parts of 9-(2-furanylmethyl)-N-(4-piperidinyl)-9H-purin-8-amine hemihydrate. The aqueous phase was extracted with dichloromethane. The organic layer was dried, filtered and evaporated. The oily residue was stirred in acetonitrile and
- 5 2,2'-oxybispropane. The product was filtered off and dried, yielding a second fraction of 5.6 parts of 9-(2-furanylmethyl)-N-(4-piperidinyl)-9H-purin-8-amine. Total yield 41.8 parts (86%) of 9-(2-furanylmethyl)-N-(4-piperidinyl)-9H-purin-8-amine hemihydrate; mp. 164.1°C (compound 33).
- 10 Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:
- 9-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine dihydrochloride; mp. 275.0°C (compound 34);
- N-(4-piperidinyl)-9-(2-thienylmethyl)-9H-purin-8-amine; mp. 189.6°C
- 15 (compound 35);
- N-(4-piperidinyl)-9-(2-pyridinylmethyl)-9H-purin-8-amine; mp. 194.8°C (compound 36);
- 9-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine; mp. 165.1°C (compound 37);
- 20 N-(4-piperidinyl)-9-(2-pyrazinylmethyl)-9H-purin-8-amine as a residue (compound 38); and
- 9-[(4-methoxyphenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine hemihydrate; mp. 144.1°C (compound 39).

In a similar manner there is also prepared:

- 25 9-[(2,4-dimethylphenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine (compound 40).

Example 22

- A mixture of 7.5 parts of ethyl 4-[[6-chloro-7-[(4-fluorophenyl)methyl]-7H-purin-8-yl]amino]-1-piperidinecarboxylate and 150
- 30 parts of a hydrobromic acid solution 48% in water was stirred overnight at 80°C. The reaction mixture was evaporated. The residue was stirred in 2-propanone. The product was filtered off and dried, yielding 8.5 parts (100%) of 7-[(4-fluorophenyl)methyl]-8-(4-piperidinylamino)-7H-purin-6-ol dihydrobromide as a residue (compound 41).

- 35 In a similar manner there were also prepared:

9-[(4-fluorophenyl)methyl]-8-(4-piperidinylmethyl)-9H-purin-6-ol dihydrobromide as a residue (compound 42); and

7-[(4-fluorophenyl)methyl]-8-(4-piperidinylmethyl)-7H-purin-6-ol dihydrobromide; mp. 277.8°C (compound 43).

5 Example 23

A mixture of 10.5 parts of ethyl 4-[(9-methyl-9H-purin-8-yl)amino]-1-piperidinecarboxylate and 300 parts of a hydrobromic acid solution 48% in water was stirred for 6 hours at 80°C. After evaporation, the residue was boiled in methanol. The reaction mixture was cooled and the precipitated product was filtered off, boiled in methanol again and yielded, after filtration and drying, 7.7 parts (56.6%) of 9-methyl-N-(4-piperidinyl)-9H-purin-8-amine dihydrobromide; mp. 298.3°C (compound 44).

In a similar manner there were also prepared:

15 cis-9-[(4-fluorophenyl)methyl]-N-(3-methyl-4-piperidinyl)-9H-purin-8-amine dihydrobromide (compound 45);

9-(phenylmethyl)-N-(4-piperidinyl)-9H-purin-8-amine dihydrobromide; mp. 270.9°C (compound 46);

(cis+trans)-9-[(4-fluorophenyl)methyl]-N-(3-methyl-4-piperidinyl)-9H-purin-8-amine dihydrobromide (compound 47);

20 9-[(4-fluorophenyl)methyl]-6-methyl-8-(4-piperidinylmethyl)-9H-purine as a residue (compound 48);

9-cyclopropyl-N-(4-piperidinyl)-9H-purin-8-amine; mp. 140.6°C (compound 49); and

25 N-(4-piperidinyl)-9-(4-thiazolylmethyl)-9H-purin-8-amine; mp. 208.4°C (compound 50).

In a similar manner there is also prepared:

9-[4-fluorophenyl)methyl]-N-methyl-N-(4-piperidinyl)-9H-purin-8-amine (compound 51).

30 Example 24

A mixture of 17.6 parts of 9-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-9H-purine and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was

35

filtered off and the filtrate was evaporated. The residue was taken up in water. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was converted into the ethanedioate salt in ethanol. The salt was
5 filtered off and dried, yielding 8.1 parts (38.1%) of 9-[(4-fluorophenyl)methyl]-8-(4-piperidinylmethyl)-9H-purine ethanedioate(1:2); mp. 163.9°C (compound 52).

In a similar manner there were also prepared:

7-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-7H-purin-8-amine as a
10 residue (compound 53); and
9-[(4-fluorophenyl)methyl]-6-methoxy-8-(4-piperidinylmethyl)-9H-purine (compound 54).

Example 25

A mixture of 15 parts of 6-chloro-7-[(4-fluorophenyl)methyl]-
15 8-[[1-(phenylmethyl)-4-piperidinyl]-methyl]-7H-purine, 5 parts of calcium oxide and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was
20 evaporated. The residue was taken up in water. The product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 ---> 85:15 by volume) as eluent. The
25 pure fractions were collected and the eluent was evaporated, yielding 5.8 parts (54%) of 7-[(4-fluorophenyl)methyl]-8-(4-piperidinylmethyl)-7H-purine as a residue (compound 55).

Example 26

A mixture of 16.25 parts of 9-[(4-fluorophenyl)methyl]-
30 8-[[1-(phenylmethyl)-4-piperidinyl]oxy]-9H-purine and 200 parts of methanol was hydrogenated at normal pressure and at 50°C with 3 parts of palladium-on-charcoal catalyst 10% and 6 parts of Raney-nickel catalyst. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was
35 evaporated. The residue was taken up in trichloromethane and water

was added. The product was extracted with trichloromethane. The extract was washed with water, dried, filtered and evaporated. The residue was stirred in 1,1'-oxybisethane. The precipitated product was filtered off and dried, yielding 10.5 parts (82.2%) of

5 9-[(4-fluorophenyl)methyl]-8-(4-piperidinyloxy)-9H-purine;
mp. 79.3°C (compound 56).

Example 27

A mixture of 3.2 parts of 2,3-dihydro-1,4-benzodioxin-2-methanol
4-methylbenzenesulfonate(ester), 5 parts of 9-[(4-fluorophenyl)-
10 methyl]-8-(4-piperidinylmethyl)-9H-purin-6-ol dihydrobromide, 3
parts of sodium carbonate and 45 parts of N,N-dimethylacetamide was
stirred overnight at 70°C. After cooling, the reaction mixture was
filtered over diatomaceous earth and the filtrate was evaporated.
The residue was purified by column chromatography over silica gel
15 using a mixture of trichloromethane and methanol, saturated with
ammonia, (90:10 by volume) as eluent. The pure fractions were
collected and the eluent was evaporated. The residue was
crystallized twice: first from acetonitrile and then from ethanol.
The product was filtered off and dried, yielding 0.8 parts (16.3%)
20 of 8-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-
methyl]-9-[(4-fluorophenyl)methyl]-9H-purin-6-ol; mp. 200.7°C
(compound 57).

In a similar manner there was also prepared:

8-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-
25 amino]-7-[(4-fluorophenyl)methyl]-7H-purin-6-ol; mp. 257.5°C
(compound 58).

Example 28

A mixture of 3.2 parts of 2,3-dihydro-1,4-benzodioxin-2-methanol
4-methylbenzenesulfonate (ester), 4.5 parts of 7-[(4-fluorophenyl)-
30 methyl]-8-(4-piperidinylmethyl)-7H-purin-6-ol dihydrobromide, 4
parts of sodium carbonate and 45 parts of N,N-dimethylformamide was
stirred overnight at 70°C. After cooling, the reaction mixture was
filtered over diatomaceous earth and the filtrate was evaporated.
The residue was purified by column chromatography over silica gel
35 using a mixture of trichloromethane and methanol, saturated with

ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 1.5 parts (34%) of 8-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]methyl]-7-[(4-fluorophenyl)-methyl]-7H-purin-6-ol; mp. 175.2°C (compound 59).

In a similar manner there were also prepared:


N-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-9-(2-furanyl-methyl)-9H-purin-8-amine dihydrochloride dihydrate; mp. 174.4°C (compound 60); and

N-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-9-[(5-methyl-2-furanyl)methyl]-9H-purin-8-amine; mp. 200.8°C (compound 61).

Example 29

A mixture of 1.9 parts of 1-(2-chloroethyl)-4-methoxybenzene, 5 parts of 7-[(4-fluorophenyl)methyl]-8-(4-piperidinylmethyl)-7H-purin-6-ol dihydrobromide, 4 parts of sodium carbonate and 45 parts of N,N-dimethylacetamide was stirred overnight at 70°C. After cooling, the reaction mixture was filtered over diatomaceous earth and the filtrate was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 2.2 parts (46%) of 7-[(4-fluorophenyl)-methyl]-8-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-7H-purin-6-ol; mp. 122.2°C (compound 62).

In a similar manner there were also prepared:



No.	L	R ²	B	R ¹	-A ¹ =A ² -A ³ =A ⁴ -	isom. mp. form °C
5	63	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	CH ₂	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C(OH)- - 197.0
	64	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	O	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C- - 120.0
	65	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	CH ₃	NH	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C- cis 160.5
	66	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	NH	CH ₃ -	-N=C-N=C- - 136.5
	67	4-CH ₃ O-C ₆ H ₄ -CH ₂ -	H	NH	4-F-C ₆ H ₄ -CH ₂ -	-C=N-C=N- - 216.0
10	68	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	NH	cyclopropyl-	-N=C-N=C- - 166.1
	69	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	NH	4-thiazolyl-CH ₂ -	-N=C-N=C- - 152.2
	70	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	NH	4-CH ₃ O-C ₆ H ₄ -CH ₂ -	-N=C-N=C- - 167.8
	71	4-CH ₃ O-C ₆ H ₄ -C ₂ H ₅ -	H	S	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C- - 102.0

15

In a similar manner there are also prepared:

9-[(4-fluorophenyl)methyl]-8-[[1-[2-(2-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-9H-purine (compound 72).


9-[(4-fluorophenyl)methyl]-N-methyl-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-9H-purin-8-amine (compound 73).

20

Example 30

A mixture of 2 parts of 1-(2-chloroethyl)-4-methoxybenzene, 3.1 parts of N-(4-piperidinyl)-9-(2-pyridinylmethyl)-9H-purin-8-amine, 1.5 parts of sodium carbonate and 45 parts of N,N-dimethylformamide was stirred overnight at 70°C. The reaction mixture was poured into water. The product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 2.2 parts (50%) of N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-9-(2-pyridinylmethyl)-9H-purin-8-amine; mp. 144.5°C (compound 74).

35



5

No.	R ¹	-A ¹ =A ² -A ³ =A ⁴ -	Base or salt form	mp. °C
75	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	base	170.6
76	2-furanyl-CH ₂ -	-N=C-N=C-	base	140.6
77	2-thienyl-CH ₂ -	-N=C-N=C-	hemihydrate	135.9
78	4-F-C ₆ H ₄ -CH ₂ -	-C=N-C=N-	base	194.9
79	5-CH ₃ -2-furanyl-CH ₂ -	-N=C-N=C-	base	164.9
80	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	(E)-2-butenedioate(2:3)	156.2
81	4-F-C ₆ H ₄ -CH ₂ -	-C=N-C=N-	base	139.1
82	4-F-C ₆ H ₄ -CH ₂ -	-C(OH)=N-C=N-	monohydrate	222.4
83	C ₆ H ₅ -CH ₂ -	-N=C-N=C-	base	161.5
84	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C(CH ₃)-	(E)-2-butenedioate(1:2)	148.0

20

In a similar manner there was also prepared:

ethyl [2-[4-[[9-(2-thienylmethyl)-9H-purin-8-yl]amino]-1-piperidinyl]ethyl]carbamate as a residue (compound 85).

In a similar manner there is also prepared:

9-[(4-fluorophenyl)methyl]-8-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]sulfonyl]-9H-purine (E)-2-butenedioate(1:2) (compound 86).

25


Example 31

A mixture of 1.45 parts of 3-(2-chloroethyl)-2-methyl-4H-pyrido-[1,2-a]pyrimidin-4-one, 2 parts of N-(4-piperidinyl)-9-(2-pyrazinyl-methyl)-9H-purin-8-amine, 1 part of sodium carbonate and 45 parts of N,N-dimethylacetamide was stirred and heated overnight at 90°C. The reaction mixture was poured into water. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol,

30


35

saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 0.9 parts (31.6%) of 2-methyl-3-[2-[4-[[9-(2-pyrazinylmethyl)-9H-purin-8-yl]amino]-1-piperidinyl]-ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 180.1°C (compound 87).



No.	B	R ¹	R ²	-A ¹ =A ² -A ³ =A ⁴ -	Base or salt form	mp. °C
15						
88	NH	2-furanyl-CH ₂ -	H	-N=C-N=C-	H ₂ O	176.6
89	NH	2-thienyl-CH ₂ -	H	-N=C-N=C-	base	194.3
90	NH	2-pyridinyl-CH ₂ -	H	-N=C-N=C-	base	201.3
91	NH	5-CH ₃ -2-furanyl-CH ₂ -	H	-N=C-N=C-	base	208.1
20						
92	CH ₂	4-F-C ₆ H ₄ -CH ₂ -	H	-N=C-N=C-	(E)-2-butenedioate (2:5)	180.0
93	NH	4-F-C ₆ H ₄ -CH ₂ -	H	-C=N-C=N-	base	211.5
94	CH ₂	4-F-C ₆ H ₄ -CH ₂ -	H	-C=N-C=N-	3HCl.2H ₂ O	217.5
25						
95	CH ₂	4-F-C ₆ H ₄ -CH ₂ -	H	-N=C-N=C(OH)-	1/2H ₂ O	196.5
96	NH	4-F-C ₆ H ₄ -CH ₂ -	H	-C(OH)=N-C=N-	H ₂ O	201.9
97	CH ₂	4-F-C ₆ H ₄ -CH ₂ -	H	-C(OH)=N-C=N-	base	210.1
98	O	4-F-C ₆ H ₄ -CH ₂ -	H	-N=C-N=C-	base	152.4
30						
99	NH	CH ₃ -	H	-N=C-N=C-	1/2 H ₂ O	213.0
100	NH	C ₆ H ₅ -CH ₂ -	H	-N=C-N=C-	base	239.2
101	NH	4-F-C ₆ H ₄ -CH ₂ -	3-CH ₃	-N=C-N=C-	base/cis+trans	212.5
102	NH	4-F-C ₆ H ₄ -CH ₂ -	H	-N=C-N=C(CH ₃)-	base	148.9
35						
103	NH	4-thiazolyl-CH ₂ -	H	-N=C-N=C-	base	222.0

In a similar manner there were also prepared:



10

No.	B	R ¹	-A ¹ =A ² -A ³ =A ⁴ -	Base or salt form	mp. °C
104	NH	2-furanyl-CH ₂ -	-N=C-N=C-	base	181.6
105	NH	2-thienyl-CH ₂ -	-N=C-N=C-	H ₂ O	168.2
106	NH	2-pyridinyl-CH ₂ -	-N=C-N=C-	H ₂ O	164.7
15 107	NH	5-CH ₃ -2-furanyl-CH ₂ -	-N=C-N=C-	base	173.4

In a similar manner there were also prepared:

- 3-[2-[4-[[9-[(4-fluorophenyl)methyl]-6-hydroxy-9H-purin-8-yl]-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido-
 20 [1,2-a]pyrimidin-4-one; mp. 171.1°C (compound 108);
 1-[3-[4-[[9-[(4-fluorophenyl)methyl]-6-methoxy-9H-purin-8-yl]-methyl]-1-piperidinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one
 (E)-2-butenedioate(2:3); mp. 179.9°C (compound 109);
 9-[(4-fluorophenyl)methyl]-N-[1-[2-(4-morpholinyl)ethyl]-4-
 25 piperidinyl]-9H-purin-8-amine; mp. 176.8°C (compound 110);
 7-methyl-6-[2-[4-[[9-(2-thienylmethyl)-9H-purin-8-yl]amino]-1-piperidinyl]ethyl]-5H-thiazolo[3,2-a]pyrimidin-5-one hemihydrate;
 mp. 104.5°C (compound 111);
 1-ethyl-4-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-
 30 1-piperidinyl]ethyl]-1,4-dihydro-5H-tetrazol-5-one; mp. 160.3°C
 (compound 112); and
 3-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-
 piperidinyl]ethyl]-2,4-(1H,3H)quinazolinedione; mp. 241.0°C
 (compound 113).

Example 32

A mixture of 1.8 parts of 1-(3-chloropropyl)-1,3-dihydro-2H-benzimidazol-2-one, 2.7 parts of 9-[(4-fluorophenyl)methyl]-8-(4-piperidinylmethyl)-9H-purine, 1 part of sodium carbonate and 45 parts of N,N-dimethylformamide was stirred and heated overnight at 70°C. After cooling, the reaction mixture was poured into water. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the (E)-2-butenedioate salt in ethanol. The salt was filtered off and dried, yielding 2.85 parts (45.9%) of 1-[3-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]methyl]-1-piperidinyl]-propyl]-1,3-dihydro-2H-benzimidazol-2-one (E)-2-butenedioate(1:2); mp. 186.2°C (compound 114).

In a similar manner there were also prepared:

1-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-piperidinyl]-ethyl]-1,3-dihydro-2H-benzimidazol-2-one; mp. 242.4°C (compound 115);
1-[3-[4-[[9-[(4-fluorophenyl)methyl]-6-hydroxy-9H-purin-8-yl]methyl]-1-piperidinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; mp. 245.8°C (compound 116).

In a similar manner there are also prepared:

3,7-dimethyl-6-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]-methyl]-1-piperidinyl]ethyl]-5H-thiazolo[3,2-a]pyrimidin-5-one (compound 117);
3-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]thio]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 118);
3-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]sulfonyl]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 119).

Example 33

A mixture of 1.2 parts of bromo-1-propene, 3.26 parts of 9-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine, 1.5


parts of sodium hydrogen carbonate and 40 parts of ethanol was stirred for 1 hour at reflux temperature. The reaction mixture was filtered over diatomaceous earth while hot and the filtrate was evaporated. The residue was taken up in water and the product was
5 extracted with 4-methyl-2-pentanone. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue
10 was crystallized from acetonitrile. The product was filtered off and dried, yielding 0.8 parts (22%) of 9-[(4-fluorophenyl)methyl]-N-[1-(2-propenyl)-4-piperidiny]-9H-purin-8-amine; mp. 144.8°C (compound 120).

In a similar manner there was also prepared:

15 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-N-(1-methylethyl)-1-piperidinepropanamide (E)-2-butenedioate(1:2); mp. 202.5°C (compound 121).

Example 34

A mixture of 3.46 parts of N-(dihydro-3,3-diphenyl-2(3H)-
20 furanylidene)-N-methylemethanaminium bromide, 3.1 parts of N-(4-piperidiny)-9-(2-pyridinylmethyl)-9H-purin-8-amine, 1.5 parts of sodium carbonate and 45 parts of N,N-dimethylacetamide was stirred overnight at 80°C. After cooling, the reaction mixture was poured into water and the product was extracted with 4-methyl-2-
25 pentanone. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from
30 acetonitrile. The product was filtered off and dried, yielding 4.1 parts (71%) of N,N-dimethyl- α,α -diphenyl-4-[[9-(2-pyridinylmethyl)-9H-purin-8-yl]amino]-1-piperidinebutanamide; mp. 191.6°C (compound 122).



5

No.	B	R ¹	-A ¹ =A ² -A ³ =A ⁴ -	Base or salt form	mp. °C
10	123 NH	5-CH ₃ -2-furanyl-CH ₂ -	-N=C-N=C-	1/2 H ₂ O	87.5
	124 NH	C ₆ H ₅ -CH ₂ -	-N=C-N=C-	base	204.2
	125 NH	2-furanyl-CH ₂ -	-N=C-N=C-	base	201.5
	126 CH ₂	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C(OH)-	base	139.2
15	127 NH	2-thienyl-CH ₂ -	-N=C-N=C-	base	197.7
	128 NH	4-F-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	2HCl	208.6
	129 NH	cyclopropyl	-N=C-N=C-	(E)-2-butendioate (2:5)	172
20	130 NH	4-CH ₃ O-C ₆ H ₄ -CH ₂ -	-N=C-N=C-	(E)-2-butendioate (2:5)	132.3

In a similar manner there were also prepared:

N,N,γ-trimethyl-α,α-diphenyl-4-[[9-(2-pyridinylmethyl)-9H-purin-8-yl]amino]-1-piperidinebutanamide; mp. 143.0°C (compound 131);
 4-[(9-methyl-9H-purin-8-yl)amino]-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide (compound 132);
γ,N,N-trimethyl-4-[[9-(2-pyridinylmethyl)-9H-purin-8-yl]methyl-α,α-diphenyl-1-piperidinebutanamide (compound 133);
 4-[[9-(2-furanylmethyl)-9H-purin-8-yl]amino]-γ,N,N-trimethyl-α,α-diphenyl-1-piperidinebutanamide (compound 134); and
γ,N,N-trimethyl-4-[[9-[(5-methyl-2-furanyl)methyl]-9H-purin-8-yl]-amino]-α,α-diphenyl-1-piperidinebutanamide (compound 135).

In a similar manner there are also prepared:

α,N,N-trimethyl-4-[[9-(2-pyridinylmethyl)-9H-purin-8-yl]amino]-α,α-diphenyl-1-piperidinebutanamide (compound 136); and

35

4-[[9-[(4-fluorophenyl)methyl]-N,N-dimethyl- α,α -diphenyl-9H-purin-8-yl]oxy]-1-piperidinebutanamide (compound 137).

Example 35

A mixture of 4.9 parts of 9-[(4-fluorophenyl)methyl]-N-
5 (4-piperidinyl)-9H-purin-8-amine, 1 part of a solution of thiophene
in methanol 4%, 120 parts of methanol and 8 parts of 2-propanone was
hydrogenated at normal pressure and at room temperature with 2 parts
of palladium-on-charcoal catalyst 10%. After the calculated amount
of hydrogen was taken up, the catalyst was filtered off and the
10 filtrate was evaporated. The residue was purified by column
chromatography over silica gel using a mixture of trichloromethane
and methanol (90:10 by volume) as eluent. The pure fractions were
collected and the eluent was evaporated. The residue was
crystallized from acetonitrile, yielding 1.5 parts (27.2%) of
15 9-[(4-fluorophenyl)methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-
9H-purin-8-amine; mp. 185.6°C (compound 138).

Example 36

A mixture of 3 parts of poly(oxymethylene), 5 parts of
7-[(4-fluorophenyl)methyl]-8-(4-piperidinylamino)-7H-purin-6-ol
20 dihydrobromide, 1 part of a solution of thiophene in methanol 4%, 5
parts of potassium acetate and 120 parts of methanol was
hydrogenated at normal pressure and at room temperature with 2 parts
of palladium-on-charcoal catalyst 10%. After the calculated amount
of hydrogen was taken up, the catalyst was filtered off and the
25 filtrate was evaporated. The residue was taken up in water and the
whole was treated with sodium carbonate. The product was extracted
with dichloromethane. The extract was dried, filtered and
evaporated. The residue was purified by column chromatography over
silica gel using a mixture of trichloromethane and methanol,
30 saturated with ammonia, (95:5 by volume) as eluent. The pure
fractions were collected and the eluent was evaporated. The residue
was crystallized from acetonitrile. The product was filtered off and
dried, yielding 2 parts (56%) of 7-[(4-fluorophenyl)methyl]-
8-[(1-methyl-4-piperidinyl)amino]-7H-purin-6-ol; mp. 255.6°C
35 (compound 139).

In a similar manner there was also prepared:

9-[(4-fluorophenyl)methyl]-8-[(1-methyl-4-piperidinyl)methyl]-9H-purin-6-ol mp. 219.0°C (compound 140).

Example 37

- 5 A mixture of 1.93 parts of 2-ethenylpyridine, 5 parts of 9-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine and 80 parts of 1-butanol was stirred and refluxed overnight. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel using first a mixture of trichloro-
- 10 methane and methanol (95:5 by volume) and then a mixture of trichloromethane and methanol, saturated with ammonia (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile, yielding 1 part (15%) of 9-[(4-fluorophenyl)methyl]-N-[1-[2-
- 15 (2-pyridinyl)ethyl]-4-piperidinyl]-9H-purin-8-amine; mp. 172.3°C (compound 141).

In a similar manner there were also prepared:

- 9-(2-furanylmethyl)-N-[1-[2-(2-pyridinyl)ethyl]-4-piperidinyl]-9H-purin-8-amine; mp. 144.5°C (compound 142);
- 20 N-[1-[2-(2-pyridinyl)ethyl]-4-piperidinyl]-9-(2-thienylmethyl)-9H-purin-8-amine; mp. 152.7°C (compound 143);
- N-[1-[2-(2-pyridinyl)ethyl]-4-piperidinyl]-9-(2-pyridinylmethyl)-9H-purin-8-amine; mp. 163.8°C (compound 144); and
- 9-[(5-methyl-2-furanyl)methyl]-N-[1-[2-(2-pyridinyl)ethyl]-4-
- 25 piperidinyl]-9H-purin-8-amine; mp 163.2°C (compound 145).

Example 38


- During 30 minutes, gaseous oxirane was bubbled through a stirred mixture of 5 parts of 9-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine and 80 parts of methanol at room temperature. After
- 30 stirring for 3 hours at room temperature, the reaction mixture was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue
- 35 was crystallized from acetonitrile, yielding 2.2 parts (40%) of

4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-piperidine-ethanol; mp. 158.7°C (compound 146).

Example 39

A mixture of 3.22 parts of 2-chloroacetonitrile, 16 parts of 9-[(4-fluorophenyl)methyl]-N-(4-piperidynyl)-9H-purin-8-amine, 12.7 parts of sodium carbonate and 225 parts of N,N-dimethylformamide was stirred for 6 hours at room temperature. The reaction mixture was poured onto water. The product was extracted twice with trichloromethane. The combined extracts were dried, filtered and evaporated. The residue was crystallized from acetonitrile. The precipitate was filtered off and the filtrate was evaporated, yielding 16 parts of 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-piperidineacetonitrile as a residue (compound 147).

In a similar manner there were also prepared:



20


No.	L	R ¹	B	-A ¹ =A ² -A ³ =A ⁴ -	mp. °C
148	NC-CH ₂ -	2-furanyl-CH ₂ -	NH	-N=C-N=C-	-
149	NC-(CH ₂) ₄ -	2-furanyl-CH ₂ -	NH	-N=C-N=C-	-
150	NC-CH ₂ -	2-pyridinyl-CH ₂ -	NH	-N=C-N=C-	-
151	NC-CH ₂ -	5-CH ₃ -2-furanyl-CH ₂ -	NH	-N=C-N=C-	-
152	NC-CH ₂ -	4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C(OCH ₃)-	-
153	NC-CH ₂ -	4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C(OH)-	-
154	NC-CH ₂ -	4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C-	-

35

Example 40

A mixture of 18.2 parts of 4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-piperidineacetonitrile and 240 parts of methanol saturated with ammonia was hydrogenated at normal pressure and at a temperature below 20°C with 3 parts of Raney-nickel catalyst. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 16 parts (87.5%) of N-[1-(2-aminoethyl)-4-piperidiny]-9-[(4-fluorophenyl)methyl]-9H-purin-8-amine; mp. 146.1°C (compound 155).

In a similar manner there were also prepared:



No.	L	R ¹	B	-A ¹ =A ² -A ³ =A ⁴ -	mp. °C
156	NH ₂ -(CH ₂) ₂ -	2-furanyl-CH ₂ -	NH	-N=C-N=C-	-
157	NH ₂ -(CH ₂) ₅ -	2-furanyl-CH ₂ -	NH	-N=C-N=C-	-
158	NH ₂ -(CH ₂) ₂ -	2-pyridinyl-CH ₂ -	NH	-N=C-N=C-	-
25 159	NH ₂ -(CH ₂) ₂ -	5-CH ₃ -2-furanyl-CH ₂ -	NH	-N=C-N=C-	-
160	NH ₂ -(CH ₂) ₂ -	4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C(OCH ₃)-	-
161	NH ₂ -(CH ₂) ₂ -	4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C(OH)-	-
162	NH ₂ -(CH ₂) ₂ -	4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C-	-


Example 41

A mixture of 10 parts of ethyl [2-[4-[[9-(2-thienylmethyl)-9H-purin-8-yl]amino]-1-piperidiny]ethyl]carbamate, 10 parts of potassium hydroxide and 240 parts of 2-propanol was stirred overnight at reflux temperature. The reaction mixture was evaporated. Water was added. After stirring, the product was

filtered off and dried, yielding 3.6 parts (56%) of N-[1-(2-aminoethyl)-4-piperidinyl]-9-(2-thienylmethyl)-9H-purin-8-amine (compound 163).

Example 42

- 5 A mixture of 1.7 parts of 2-chloropyrimidine, 5.5 parts of N-[1-(2-aminoethyl)-4-piperidinyl]-9-[(4-fluorophenyl)methyl]-9H-purin-8-amine, 1.5 parts of sodium hydrogen carbonate and 160 parts of ethanol was stirred and refluxed for 20 hours. The reaction mixture was evaporated. The residue was purified by column
10 chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile, yielding 4.5 parts (67%) of
15 9-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-9H-purin-8-amine; mp. 164.1°C (compound 164).



No.	R ¹	B	-A ¹ =A ² -A ³ =A ⁴ -	base or salt form	mp. °C
25	165 2-furanyl-CH ₂ -	NH	-N=C-N=C-	base	135.5
	166 2-pyridinyl-CH ₂ -	NH	-N=C-N=C-	base	140.1
	167 2-thienyl-CH ₂ -	NH	-N=C-N=C-	base	157.2
	168 5-CH ₃ -2-furanyl-CH ₂ -	NH	-N=C-N=C-	base	174.1
	169 4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C(OCH ₃)-	base	138.1
30	170 4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C(OH)-	base	212.9
	171 4-F-C ₆ H ₄ -CH ₂ -	CH ₂	-N=C-N=C-	ethanedioate (1:3)	102.1

evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 1.3 parts (29%) of N-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]amino]-1-piperidinyl]ethyl]-N'-methylthiourea; mp. 205.5°C (compound 179).

5 In a similar manner there is also prepared:

N-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]methyl]-1-piperidinyl]ethyl]-N'-ethylurea; (compound 180).

Example 47

To a stirred and cooled (-10°C) mixture of 5.6 parts of
10 N,N'-methanetetraylbis[cyclohexanamine], 13.9 parts of carbon disulfide and 90 parts of tetrahydrofuran were added portionwise 10 parts of N-[1-(2-aminoethyl)-4-piperidinyl]-9-[(4-fluorophenyl)-methyl]-9H-purin-8-amine. Upon completion, the temperature was allowed to rise to room temperature and the reaction mixture was
15 evaporated, yielding 16 parts of 9-[(4-fluorophenyl)methyl]-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-9H-purin-8-amine (compound 181).

A mixture of 2.95 parts of 3,4-pyridinediamine, 16 parts of 9-[(4-fluorophenyl)methyl]-N-[1-(2-isothiocyanatoethyl)-4-piperi-
20 dinyl]-9H-purin-8-amine, and 90 parts of tetrahydrofuran was stirred and refluxed overnight. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95/5 by volume) as eluent. The pure fractions were collected and
25 the eluent was evaporated, yielding 10.5 parts of N-(4-amino-3-pyridinyl)-N'-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]-amino]-1-piperidinyl]ethyl]thiourea (compound 182).

A mixture of 10.5 parts of N-(4-amino-3-pyridinyl)-N'-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]-amino]-1-piperidinyl]-
30 ethyl]thiourea, 6 parts of mercury(II) oxide, 1 part of sulfur and 120 parts of ethanol was stirred and refluxed overnight. The reaction mixture was filtered over Hyflo® while hot. The filtrate was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol,
35 saturated with ammonia, (90:10 by volume) as eluent. The pure

fractions were collected and the eluent was evaporated. The residue was converted into the (E)-2-butenedioate salt in ethanol. The salt was filtered off and dried, yielding 4 parts (17%) of 9-[(4-fluorophenyl)methyl]-N-[1-[2-[(1H-imidazo[4,5-c]pyridin-2-yl)amino]ethyl]-4-piperidinyl]-9H-purin-8-amine (E)-2-butenedioate(1:3) monohydrate; mp. 191.0°C (compound 183).

Example 48

To a previously prepared sodium methoxide solution, starting from 25 parts of sodium in 400 parts of methanol, were added 49.4 parts of 6-chloro-9-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-9H-purine. After stirring for 8 hours at reflux temperature, the reaction mixture was cooled and 1000 parts of water were added. The precipitated product was filtered off and dried, yielding 34.5 parts (70.4%) of 9-[(4-fluorophenyl)methyl]-6-methoxy-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-9H-purine (compound 184).

Example 49

A mixture of 3 parts of 6-chloro-9-[(4-fluorophenyl)methyl]-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-9H-purine and 50 parts of a hydrochloric acid solution 1N was stirred and refluxed for 1.5 hours. After cooling, the mixture was made alkaline with ammonium hydroxide. The product was extracted with trichloromethane. The extract was washed with water, dried, filtered and evaporated. The residue was crystallized from a mixture of acetonitrile and ethanol. The product was filtered off and dried, yielding 1.5 parts (52%) of 9-[(4-fluorophenyl)methyl]-1,9-dihydro-8-[[1-(phenylmethyl)-4-piperidinyl]methyl]-6H-purin-6-one; mp. 197.0°C (compound 185).

Example 50

A mixture of 2.7 parts of 9-[(4-fluorophenyl)methyl]-8-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-9H-purin-6-ol and 75 parts of a hydrobromic acid solution 48% in water was stirred for 4 hours at 80°C. After evaporation, the residue was taken up in water and treated with sodium carbonate. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over

silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (90:10 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from ethanol and acetonitrile. The product was
5 filtered off and dried, yielding 1 part (38.6%) of 9-[(4-fluorophenyl)methyl]-8-[[1-[2-(4-hydroxyphenyl)ethyl]-4-piperidinyl]-methyl]-9H-purin-6-ol; mp. 215.7°C (compound 186).

In a similar manner there was also prepared:

4-[[4-[[7-[(4-fluorophenyl)methyl]-7H-purin-8-yl]amino]-1-piperidinyl]methyl]phenol; mp. 228.1°C (compound 187).
10

In a similar manner there is also prepared:

2-[2-[4-[[9-[(4-fluorophenyl)methyl]-9H-purin-8-yl]methyl]-1-piperidinyl]ethyl]phenol (compound 188).

Example 51

15 To a stirred solution of 7.2 parts of 4-[[9-[(4-fluorophenyl)-methyl]-9H-purin-8-yl]thio]-1-[(4-methylphenyl)sulfonyl]piperidine in 195 parts of dichloromethane is added dropwise a solution of 7 parts of 3-chlorobenzenecarboperoxoic acid in 65 parts of dichloromethane. Upon completion, stirring is continued for 2 hours
20 at room temperature. The whole is washed with a sodium carbonate solution and twice with water, dried, filtered and evaporated. The residue is crystallized from acetonitrile. The product is filtered off and dried, yielding 3 parts (40%) of 4-[[9-[(4-fluorophenyl)-methyl]-9H-purin-8-yl]sulfonyl]-1-[(4-methylphenyl)sulfonyl]-
25 piperidine; (compound 189).

30

35

C. Pharmacological Examples

The useful antihistaminic properties of the compounds of formula (I) are demonstrated in the following test procedure.

5

Example 52Protection of rats from compound 48/80-induced lethality.

Compound 48/80, a mixture of oligomers obtained by condensation of 4-methoxy-N-methylbenzeneethanamine and formaldehyde has been described as a potent histamine releasing agent (Int. Arch. Allergy, 13, 336 (1958)). The protection from compound 48/80-induced lethal circulatory collapse appears to be a simple way of evaluating quantitatively the antihistaminic activity of test compounds. Male rats of an inbred Wistar strain, weighing 240-260 g were used in the experiment. After overnight starvation the rats were transferred to conditioned laboratories (temp. = $21 \pm 1^\circ\text{C}$, relative humidity = $65 \pm 5\%$). The rats were treated subcutaneously or orally with a test compound or with the solvent (NaCl solution, 0.9%). One hour after treatment there was injected intravenously compound 48/80, freshly dissolved in water, at a dose of 0.5 mg/kg (0.2 ml/100 g of body weight). In control experiments, wherein 250 solvent-treated animals were injected with the standard dose of compound 48/80, not more than 2.8% of the animals survived after 4 hours. Survival after 4 hours is therefore considered to be a safe criterion of a protective effect of drug administration.

25

The ED_{50} -values of the compounds of formula (I) are listed in Table 1. Said ED_{50} -values are the values in mg/kg body weight at which the tested compounds protect 50% of the tested animals against compound 48/80-induced lethality.

30

35

Table 1

Compound No.	compound 48/80 lethality test in rats-ED ₅₀ in mg/kg body weight
60	0.08
61	0.01
62	0.04
64	0.08
74	0.01
75	0.08
76	0.02
77	0.02
78	0.04
79	0.04
80	0.04
81	0.04
83	0.08
87	0.08
88	0.02
89	0.08
100	0.02
104	0.04
106	0.08
107	0.02
114	0.04
115	0.08
141	0.01
142	0.02
143	0.02
144	0.04
145	0.01
165	0.02

Compound No.	compound. 48/80 lethality test in rats-ED ₅₀ in mg/kg body weight
167	0.08
168	0.02
169	0.08
171	0.08
172	0.04
173	0.08
183	0.04

D) Composition Examples

The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic administration to animal and human subjects in accordance with the instant invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.

10 Example 53 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 liters of 2-hydroxypropanoic acid and 1.5 liters of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 liters of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 liters of purified water and while stirring there were added 2.5 liters of cocoa flavor and polyethylene glycol q.s. to a volume of 50 liters, providing an oral drop solution comprising 10 milligrams of the A.I. per milliliter. The resulting solution was filled into suitable containers.

20 Example 54 : ORAL SOLUTION

9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 liters of boiling purified water. In 3 liters of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 liters 1,2,3-propanetriol and 3 liters of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were dissolved in 0.5 liters of water and 2 milliliters of raspberry and 2 milliliters of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 liters providing an oral solution comprising 20 milligrams of the active ingredient per teaspoonful (5 milliliters). The resulting solution was filled in suitable containers.

Example 55 : CAPSULES

20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously stirred together. The
5 resulting mixture was subsequently filled into 1000 suitable hardened gelating capsules, comprising each 20 milligrams of the active ingredient.

Example 56 : FILM-COATED TABLETSPreparation of tablet core

10 A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone (Kollidon-K 90®) in about 200 milliliters of water. The wet powder
15 mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose (Avicel®) and 15 grams hydrogenated vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 milligrams of the active ingredient.

Coating

20 To a solution of 10 grams methyl cellulose (Methocel 60 HG®) in 75 milliliters of denaturated ethanol there was added a solution of 5 grams of ethyl cellulose (Ethocel 22 cps ®) in 150 milliliters of dichloromethane. Then there were added 75 milliliters of
25 dichloromethane and 2.5 milliliters 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 milliliters of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 milliliters of concentrated colour suspension (Opaspray K-1-2109®) and the whole was homogenated.
30 The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 57 : INJECTABLE SOLUTION

1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 liters of boiling water for
35 injection. After cooling to about 50°C there were added while stirring

4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I..

The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 liter volume, giving a solution of 4
5 milligrams A.I. per milliliters. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Example 58 : SUPPOSITORIES

3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxy-
butanedioic acid in 25 milliliters polyethylene glycol 400. 12 Grams
10 surfactant (SPAN®) and triglycerides (Witepsol 555 ®) q.s. ad 300
grams were molten together. The latter mixture was mixed well with the
former solution. The thus obtained mixture was poured into moulds at a
temperature of 37~38°C to form 100 suppositories each containing 30
milligrams of the active ingredient.

15

20


25

30

35

CLAIMS


- 1 1. A chemical compound having the formula



- 2 a pharmaceutically acceptable acid addition salt or a possible
 3 stereochemically isomeric form thereof, wherein:
 4 $-A^1=A^2-A^3=A^4-$ is a bivalent radical having the formula
 5 $-N=CH-N=CH-$ (a-1), or
 6 $-CH=N-CH=N-$ (a-2),
 7 wherein one or two hydrogen atoms in said radicals (a-1) or (a-2) may,
 8 each independently from each other, be replaced by halo, C_{1-6} alkyl,
 9 C_{1-6} alkyloxy, trifluoromethyl or hydroxy;
 10 R^1 is a member selected from the group consisting of hydrogen,
 11 C_{1-10} alkyl, C_{3-6} cycloalkyl, Ar^1 and C_{1-6} alkyl substituted with one
 12 or two Ar^1 radicals;
 13 R^2 is a member selected from the group consisting of hydrogen and
 14 C_{1-6} alkyl;
 15 B is CH_2 , NR, O, S, SO or SO_2 ; said R being a member selected
 16 from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl,
 17 $(C_{1-6}$ alkyl)-CO-, $(C_{1-6}$ alkyloxy)-CO and Ar^2-C_{1-6} alkyl;
 18 L is a member selected from the group consisting of a radical of
 19 formula

- 20 $L^1-C_{rH_{2r}}-T-C_{sH_{2s}}-$ (b-1); and

- 21 a radical of formula




- 23 wherein one or two hydrogen atoms in the bivalent radical

- 24 $-C_{sH_{2s}}-$ may, each independently from each other, be replaced by
 25 halo, hydroxy, mercapto, isothiocyanato, isocyanato, C_{1-6} alkyloxy,
 26 C_{1-6} alkylthio, Ar^1 , Ar^1O- , Ar^1S- , Ar^1SO_2- , or NHR^3R^5 ; and
 27 n is 0 or the integer 1 or 2;
 28 r and s are, independently from each other, 0 or an integer of from 1
 29 to 6 inclusive;

30 T is $-Y-$ or $-Z-\overset{\overset{X}{||}}{C}-Y-$;

- 31 T^1 is $-Z-\overset{\overset{X}{||}}{C}-$ or a direct bond;
 32 said Y being O , S , NR^3 or a direct bond;
 33 X being O , S , $CH-NO_2$ or NR^4 ;
 34 Z being O , S , NR^5 or a direct bond; and
 35 said R^3 being hydrogen, C_{1-6} alkyl, Ar^2-C_{1-6} alkyl, 2-(C_{1-6} alkyl-
 36 oxy)-1,2-dioxoethyl or a radical of formula $-C(=X)-R^6$, R^6 being hydrogen,
 37 C_{1-6} alkyl, Ar^2 , Ar^2-C_{1-6} alkyl, C_{1-6} alkyloxy, Ar^2-C_{1-6} alkyloxy,
 38 mono- or di(C_{1-6} alkyl)amino, Ar^2 -amino, Ar^2-C_{1-6} alkylamino or
 39 Ar^2-C_{1-6} alkyl(C_{1-6} alkyl)amino;
 40 said R^4 being hydrogen, C_{1-6} alkyl, cyano, nitro, Ar^2 -sulfonyl,
 41 C_{1-6} alkylsulfonyl, C_{1-6} alkylcarbonyl or Ar^2 -carbonyl; and
 42 said R^5 being hydrogen or C_{1-6} alkyl;
 43 wherein L^1 is a member selected from the group consisting of hydro-
 44 gen; halo; hydroxy; C_{1-6} alkyloxy; C_{1-6} alkylthio; cyano; mercapto;
 45 isocyanato; isothiocyanato; Ar^1 ; Ar^1 -carbonyl; Ar^1 -sulfonyl; C_{1-6}
 46 alkylsulfonyl; C_{3-6} cycloalkyl being optionally substituted with up
 47 to two substituents each independently selected from the group
 48 consisting of C_{1-6} alkyl, cyano and Ar^2 ; [10,11-dihydro-5H-dibenzo-
 49 [a,d]cyclohepten-5-ylidene]methyl; Het; and furan substituted with
 50 substituted C_{1-6} alkyl; said substituted C_{1-6} alkyl being C_{1-6}
 51 alkyl substituted with a member selected from the group consisting of
 52 hydroxy, mercapto, C_{1-6} alkyloxy, C_{1-6} alkylthio, amino C_{1-6}
 53 alkylthio, Ar^2 -oxy and a radical of formula

54



(c).

55 wherein: t is 0 or an integer of from 1 to 6 inclusive; and
 56 R^7 is hydrogen or C_{1-6} alkyl;
 57 provided that: when in said radical of formula (c) t is 0, then Z or Y
 58 is a direct bond; and

59 where r is 0, L^1 may also be C_{2-6} alkenyl, Ar^1-C_{2-6} alkenyl or
 60 C_{1-6} alkyl substituted with two C_{1-6} alkyloxy radicals; and

61 where r is 0 and T is NR^3 , or T is $-N(R^5)-C(=X)-Y$ or T^1 is $-N(R^5)-C(=X)-$,
 62 L^1 may also be amino, C_{1-6} alkylamino or Ar^1 -amino; and

63 where r is 0, and T is $-N(R^5)-C(=X)-Y$ or T^1 is $-N(R^5)-C(=X)-$, L^1
 64 may also be nitro;

65 said Het being an optionally substituted five- or six-membered hetero-
 66 cyclic ring, being optionally condensed with an optionally substituted
 67 five- or six-membered carbocyclic or heterocyclic ring;

68 provided that:

- 69 i) when L is a radical of formula (b-1) wherein L^1 is hydrogen and
 70 wherein T is $-Z-C(=X)-Y$ wherein Y is other than a direct bond
 71 and Z and X are each independently O or S, then r is not 0; or
 72 when L is a radical of formula (b-2) wherein L^1 is hydrogen and
 73 wherein T^1 is $-Z-C(=X)-$ wherein Z and X are each independently
 74 O or S, then r is not 0;
- 75 ii) when L is a radical of formula (b-1) wherein L^1 is halo,
 76 hydroxy, C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio, isocyanato,
 77 isothiocyanato or Het connected to C_rH_{2r} on a nitrogen atom,
 78 and wherein r is 0, then T is a direct bond or a radical
 79 $-C(=X)-Y$; or when L is a radical of formula (b-2) wherein L^1
 80 is halo, hydroxy, C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio,
 81 isocyanato, isothiocyanato or Het connected to C_rH_{2r} on a

82 nitrogen atom, and wherein r is 0, then T^1 is a radical $-C(=X)-$;
 83 iii) when L is a radical of formula (b-1) wherein T is Y , said Y being
 84 other than a direct bond, or wherein T is $-Z-C(=X)-Y-$, wherein Y
 85 is other than a direct bond, then s is not 0;










86 wherein Ar^1 is a member selected from the group consisting of
 87 phenyl, substituted phenyl, naphthalenyl, thienyl, halothienyl, C_{1-6}
 88 alkylthienyl, pyridinyl, mono- and di(C_{1-6} alkyloxy)pyridinyl,
 89 pyrrolyl, C_{1-6} alkylpyrrolyl, furanyl, furanyl substituted with
 90 C_{1-6} alkyl, pyrazinyl, thiazolyl, imidazolyl, C_{1-6} alkylimidazolyl;
 91 said substituted phenyl, being phenyl substituted with up to 3
 92 substituents each independently selected from the group consisting of
 93 halo, hydroxy, nitro, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6}
 94 alkyloxy, C_{1-6} alkylthio, mercapto, amino, mono- and di(C_{1-6}
 95 alkyl)amino, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonyl C_{1-6} alkyl,
 96 phenyl C_{1-6} alkylsulfonyl, phenylsulfonyl C_{1-6} alkyl, a radical of
 97 formula $R^8-C_{p-2p}H_{2p}-Y-$, a radical of formula $R^9-Z-C(=X)-Y-$, and
 98 a radical of formula $R^{10}SO_2Y-$; wherein p is an integer of from 1
 99 to 6 inclusive and R^8 is a member selected from the group consisting
 100 of amino, cyano, phenyl aminocarbonyl, mono- and di(C_{1-6} alkyl)amino-
 101 carbonyl, C_{1-6} alkyloxycarbonyl, phenyl C_{1-6} alkyloxycarbonyl,
 102 4-morpholinylcarbonyl, 1-piperidinylcarbonyl, 1-pyrrolidinylcarbonyl,
 103 and C_{2-6} alkenyl; wherein R^9 is member selected from the group
 104 consisting of hydrogen, C_{1-6} alkyl and Ar^2 ; provided that, when
 105 R^9 is hydrogen and Y is other than a direct bond, then Z is not O or
 106 S; and wherein R^{10} is C_{1-6} alkyl or Ar^2 ;
 107 wherein Ar^2 is a member selected from the group consisting of
 108 phenyl, substituted phenyl, thienyl and furanyl, said substituted
 109 phenyl being phenyl optionally substituted with up to three
 110 substituents each independently selected from the group consisting of
 111 halo, hydroxy, nitro, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6}
 112 alkyloxy, C_{1-6} alkylthio, mercapto, amino, mono- and di(C_{1-6}
 113 alkyl)amino, carboxyl, C_{1-6} alkyloxycarbonyl and (C_{1-6} alkyl)-CO.

1 2. A chemical compound according to claim 1 wherein Het is a five-
 2 or six-membered heterocyclic ring containing a number of heteroatoms
 3 which varies of from 1 to 4, said heteroatoms being selected from the
 4 group consisting of oxygen, sulfur and nitrogen, provided that no more
 5 than two oxygens or sulfurs are present, said five or six-membered
 6 ring being optionally condensed with a five- or six-membered
 7 carbocyclic or heterocyclic ring also containing a number of
 8 heteroatoms which varies from 1 to 4, the latter heteroatoms being
 9 selected from the group consisting of oxygen, sulfur and nitrogen,
 10 provided that no more than 2 oxygens or sulfurs are present, and
 11 wherein said Het being a bicyclic ring system may optionally be
 12 substituted with up to 6 substituents, or said Het being a monocyclic
 13 ring system may optionally be substituted with up to 3 substituents,
 14 said substituents of Het being selected from the group consisting of a
 15 bivalent radical of formula =X, said =X independently having the same
 16 meaning of the previously defined X; halo; isocyanato; isothiocyanato;
 17 nitro, cyano, trifluoromethyl; a radical of formula A-Y-, wherein A is
 18 hydrogen, Ar¹ or C₁₋₆ alkyl being optionally substituted with
 19 Ar¹, C₁₋₆ alkyloxy, Ar¹O, hydroxy, C₁₋₆ alkyloxycarbonyl and Y
 20 independently has the same meaning of the previously defined Y; and a
 21 radical A-Z-C(=X)-Y-, wherein A is as defined hereinabove and Z, X and
 22 Y independently have the same meanings of the previously defined Z, X
 23 and Y; provided that (i) when in the radical A-Y- A is hydrogen, then
 24 Y is other than a direct bond, or (ii) when in the radical A-Z-C(=X)-Y-
 25 A is hydrogen and Y is NR³, O or S, then Z is other than O or S.

1 3. A chemical compound according to claim 2 wherein Het is a member
 2 selected from the group consisting of
 3 i) pyridinyl which is optionally substituted with one or two substi-
 4 tuents each independently selected from the group consisting of
 5 halo, amino, mono- and diC₁₋₆ alkylamino, Ar² C₁₋₆ alkyl-
 6 amino, nitro, cyano, aminocarbonyl, C₁₋₆ alkyl, C₁₋₆
 7 alkyloxy, C₁₋₆ alkylthio, C₁₋₆ alkyloxycarbonyl, hydroxy,
 8 C₁₋₆ alkylcarbonyloxy, Ar²-C₁₋₆ alkyl and carboxyl;
 9 pyridinyloxide optionally substituted with nitro;

- 10 quinoliny1 which is optionally substituted with C₁₋₆ alkyl;
 11 pyrimidinyl which is optionally substituted with one or two
 12 substituents each independently selected from the group
 13 consisting of halo, amino, hydroxy, C₁₋₆ alkyl, C₁₋₆
 14 alkyloxy, C₁₋₆ alkylthio and Ar²-C₁₋₆ alkyl;
 15 quinazolinyl which is optionally substituted with hydroxy or
 16 C₁₋₆ alkyl;
 17 pyridazinyl which is optionally substituted with C₁₋₆ alkyl or
 18 halo;
 19 quinoxalinyl which is optionally substituted with C₁₋₆ alkyl;
 20 pyrazinyl which is optionally substituted with halo, amino or
 21 C₁₋₆ alkyl;
 22 phthalazinyl which is optionally substituted with halo;
 23 morfolinyl;
 24 thiomorfolinyl;
 25 piperidinyl;
 26 2,3-dihydro-3-oxo-4H-benzoxazinyl and 2,3-dihydro-1,4-benzo-
 27 dioxinyl, both being optionally substituted with C₁₋₆ alkyl or
 28 halo;
 29 dioxanyl being optionally substituted with C₁₋₆ alkyl;
 30 2-oxo-2H-1-benzopyranyl and 4-oxo-4H-1-benzopyranyl both being
 31 optionally substituted with C₁₋₆ alkyl;
 32 1,4-dihydro-2,4-dioxo-3(2H)-pyrimidinyl being optionally
 33 substituted with C₁₋₆ alkyl; and
 34 4-oxo-2(1H)-pyrimidinyl;
- 35 ii) 5,6-dihydro-4H-1,3-thiazin-2-yl, thiazolyl, 4,5-dihydrothiazolyl,
 36 oxazolyl, imidazolyl, tetrazolyl, 1,3,4-thiadiazolyl, benzimi-
 37 dazolyl, benzothiazolyl, benzoxazolyl, 4,5-dihydro-5-oxo-1H-
 38 tetrazolyl, 2-oxo-3-oxazolidinyl and indolyl whereby each of the
 39 Het-radicals of group ii) may optionally be substituted where
 40 possible with up to two substituents selected from the group
 41 consisting of C₁₋₆ alkyl, Ar¹, Ar¹-C₁₋₆ alkyl, benzimida-
 42 zolyl, C₁₋₆ alkyl, amino, (aminoiminomethyl)amino, mono- and
 43 di(C₁₋₆ alkyl)amino, Ar¹-amino, nitro, C₁₋₆ alkyloxy-
 44 carbonyl and pyrimidinyl;

45 iii) a radical of formula



50 wherein each X^2 is independently O or S;

51 R^{11} , R^{12} , R^{14} , R^{22} and R^{24} are each independently hydrogen, C_{1-6}

52 alkyl, Ar^2-C_{1-6} alkyl, hydroxy C_{1-6} alkyl or C_{1-6} alkyloxycarbonyl;

53 R^{13} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} and R^{23} are each independently

54 hydrogen, C_{1-6} alkyl, hydroxy, mercapto, C_{1-6} alkyloxy, C_{1-6}

55 alkylthio, halo and $(C_{1-6}$ alkyloxycarbonyl) C_{1-6} alkyl;

56 G^1 is $-CH=CH-CH=CH-$, $-S-CH=CH-$ or $-N=CH-NH-$;

57 G^2 is $-CH=CH-CH=CH-$, $-S-(CH_2)_2-$, $-S-(CH_2)_3-$, $-(CH_2)_4-$ or $-S-CH=CH-$;

58 G^3 is $-CH=CH-CH=CH-$, $-CH_2-NH-(CH_2)_2-$, $-S-CH=CH-$, $-N=CH-CH=CH-$,

59 $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ or $-CH=N-CH=N-$;

60 G^4 is $-CH_2-NH-(CH_2)_2-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$,

61 $-\text{CH}=\text{CH}-\text{CH}-\text{N}-$, $-\text{N}=\text{CH}-\text{N}=\text{CH}-$ or $-\text{CH}=\text{N}-\text{CH}=\text{N}-$;
 62 G^5 is $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}-\text{N}-$,
 63 $-\text{N}=\text{CH}-\text{N}=\text{CH}-$ or $-\text{CH}=\text{N}-\text{CH}=\text{N}-$;
 64 G^6 is $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$,
 65 $-\text{CH}=\text{CH}-\text{CH}-\text{N}-$, $-\text{N}=\text{CH}-\text{N}=\text{CH}-$ or $-\text{CH}=\text{N}-\text{CH}=\text{N}-$;
 66 wherein one or two hydrogen atoms in said radicals G^1 , G^2 , G^3 , G^4 ,
 67 G^5 or G^6 or in the benzene part of the radicals of formula (e-2),
 68 (e-3) or (e-9) may be replaced by C_{1-6} alkyl, C_{1-6} alkylthio, C_{1-6}
 69 alkyloxy or halo where said hydrogen atom is bonded on a carbon atom,
 70 or by C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, $\text{Ar}^2-\text{C}_{1-6}$ alkyl, where
 71 said hydrogen is bonded on a nitrogen atom; and wherein
 72 it is clear that R^{11} , R^{12} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{22} or R^{23} is absent
 73 where the radical of formula (e-1), respectively (e-4), (e-5), (e-6)
 74 or (e-7) is connected to C_sH_{2s} on the atom bearing R^{11} , R^{12} , R^{17} , R^{18} ,
 75 R^{19} , R^{20} , R^{21} , R^{22} or R^{23} .

1 4. A chemical compound according to claim 3 wherein L is a radical
 2 of formula (b-1).

1 5. A chemical compound according to claim 4 wherein r is 0 and
 2 L^1 is hydrogen, hydroxy, C_{1-6} alkyloxy, C_{1-6} alkylthio, mercapto,
 3 Het, Ar^1 , isocyanato, isothiocyanato or cyano.

1 6. A chemical compound according to claim 5 wherein R^1 is C_{1-6}
 2 alkyl substituted with one Ar^1 radical.

1 7. A pharmaceutical composition comprising a suitable
 2 pharmaceutical carrier and as active ingredient a therapeutically
 3 effective amount of a compound as claimed in any one of claims 1 to 6.

1 8. An anti-allergic pharmaceutical composition comprising a
2 suitable pharmaceutical carrier and as active ingredient an
3 effective anti-allergic amount of a compound as claimed in any one
4 of claims 1 to 6.


1 9. A method of preparing a pharmaceutical composition,
2 characterized in that a therapeutically effective amount of a
3 compound as defined in any of claims 1 to 6 is intimately mixed
4 with suitable pharmaceutical carriers.

1 10. A compound as claimed in any one of claims 1 to 6 for use as
2 a medicine.

1 11. A compound as claimed in any one of claims 1 to 6 for use as
2 an anti-allergic medicine.


1 12. A process for preparing a chemical compound as claimed in
2 any one of claims 1 to 6, characterized by

3 I) reacting a piperidine of formula




5 wherein X^1 is O, S or NH and W is a reactive leaving group.

6 with an aromatic diamine of formula



8 in a reaction inert medium, said reaction proceeding in some
9 instances via an intermediate of formula




11 which may in situ, or if desired, after isolating and further
12 purifying it, be cyclized to yield the desired compounds of
13 formula (I);

14 II) reacting a piperidine of formula



16 with an intermediate of formula




18 in a reaction-inert solvent, wherein:

19 i) E^1 is a radical of formula $-B-M$ wherein M is hydrogen or
20 an alkali metal or earth alkaline metal and E^2 is a
21 radical of formula $-W$; or


-90-

- 22 ii) E^1 is a radical of formula $-W$ and E^2 is a radical of
 23 formula $M-B$; or
 24 iii) E^1 is a radical of formula $-CH_2-W$ and E^2 is a radical
 25 of formula $-M$, thus preparing a compound of formula



- 27 iv) E^1 is a radical of formula $-M$ and E^2 is a radical of
 28 formula $-CH_2-W$, thus preparing a compound of formula (I-a);


29 III) i) cyclodesulfurizing an intermediate of formula



31 with an appropriate alkyl halide, metal oxide or metal salt
 32 in

32 a reaction-inert solvent; or

33 ii) cyclodesulfurizing an intermediate of formula




35 and subsequently dehydrating the thus obtained oxazole[5,4-d]-
 36 pyrimidine derivative with a suitable dehydrating agent; and,
 37 if desired, converting the compounds of formula (I) into each
 38 other by

- 39 a) alkylating a compound of formula Q^2-D (I-c) with a reagent
 40 of formula L^1-Q^1 (VII) in a suitable solvent, thus
 41 preparing a compound of formula L^2-D (I-b), wherein L^2 has
 42 the previously defined meaning of L , provided that it is other
 43 than hydrogen, and wherein


-91-

- 44 i) Q^1 is $-W$ and Q^2 is hydrogen wherein $-W$ is a
 45 reactive leaving group or taken together with L^2 a
 46 reactive cyclic agent; or
 47 ii) Q^1 is $-C_rH_{2r}-W^1$ and Q^2 is a radical of formula
 48 $HT^2-C_sH_{2s}-$, wherein W^1 is a reactive leaving
 49 group and T^2 is O, S, NR^3 or $-Z^1-C(=X)-Y-$, said
 50 Z^1 being O, S or NR^5 , thus preparing a compound of
 51 formula $L^1-C_rH_{2r}-T^2-C_sH_{2s}-D$ (I-b-1-a); or


- 52 iii) Q^1 is $-C_rH_{2r}-W^1$ and Q^2 is a radical of formula




- 54 wherein T^3 is a direct bond or $Z^1-C(=X)-$, thus
 55 preparing a compound of formula



- 57 iv) Q^1 is a radical of formula $-C_rH_{2r}-T^4H$ and
 58 Q^2 is $W-C_sH_{2s}-$, wherein T^4 is O, S, NR^3 or
 59 $-Z-C(=X)-Y^1-$, said Y^1 being O, S or NR^3 , thus
 60 preparing a compound of formula



- 62 b) reductively N-alkylating a compound of formula H-D, (I-c-1),
 63 with a carbonyl-compound of formula $L^{2-a}=C=O$ (VIII), said
 64 $L^{2-a}=C=O$ being a compound of formula L^2-H wherein a $-CH_2-$
 65 radical is oxidated to a carbonyl radical, in a reaction-inert
 66 solvent, thus preparing a compound of formula L^2-D (I-b);
 67 c) reductively N-alkylating a compound of formula



- 69 with a carbonyl-compound of formula

70 $L^1-(C_rH_{2r-1})=O$ (IX),

71 said $L^1-(C_rH_{2r-1})=O$ being a compound of formula
 72 $L^1-C_rH_{2r}-H$ wherein a $-CH_2-$ radical is oxidated to a
 73 carbonyl radical, in a reaction inert solvent, thus preparing a
 74 compound of formula

75 $L^1-C_rH_{2r}-N(R^3)-C_sH_{2s}-D$ (I-b-3);

76 d) reductively N-alkylating an intermediate of formula

77 $L^1-C_rH_{2r}-N(R^3)H$ (X)

78 with a compound of formula

79 $O=(C_sH_{2s-1})-D$ (I-e),

80 said $O=(C_sH_{2s-1})-$ being a radical of formula $H-C_sH_{2s}-$
 81 wherein a $-CH_2-$ radical is oxidated to a carbonyl radical, in a
 82 reaction-inert solvent, thus preparing a compound of formula (I-b-3);
 83 e) reacting a reagent of formula

84 $L^1-C_rH_{2r}-Z^1H$ (XI)

85 with a compound of formula

86 $X^2=C=N-C_sH_{2s}-D$ (I-f),

87 wherein X^2 is O or S, in a reaction-inert solvent, thus preparing
 88 a compound of formula

89 $L^1-C_rH_{2r}-Z^1-C(=X^2)-NH-C_sH_{2s}-D$ (I-b-4);

90 f) reacting a reagent of formula


-93-




92 with a compound of formula




94 respectively with a compound of formula H-D (I-c-1) or with a
95 compound of formula




97 in a reaction-inert solvent, thus preparing a compound of formula




99 respectively of formula




101 or of formula




103 g) reacting a reagent of formula




105 with (I-c-4), respectively with (I-c-1) or (I-c-5), in a
106 reaction-inert solvent, if desired, after converting the OH
107 group in (XIII) in a reactive leaving group or by reacting
108 (XIII) with (I-c-4), respectively (I-c-1) or (I-c-5), in the
109 presence of a reagent capable of forming esters or amides, thus
110 preparing a compound of formula




112 respectively of formula




114 or of formula




116 h) reacting (XI) with (I-c-4), respectively (I-c-1) or (I-c-5) in
 117 the presence of a $>C=X$ generating agent in a reaction-inert
 118 solvent, thus preparing a compound of formula




120 respectively of formula




122 or of formula




124 i) reacting an alkene of formula $L^1-C_rH_{2r}-T-C_{2-6}$ alkenediyl-H
 125 of formula (XIV) with (I-c-1) in a reaction-inert solvent, thus
 126 preparing a compound of formula



128 j) reacting a reagent of formula




130 in a reaction-inert solvent, thus preparing a compound of formula




132 wherein s' is an integer of from 2 to 6 inclusive;

133 k) cyclizing an imidamide of formula




135 in a reaction-inert solvent in the presence of an acid, thus
136 preparing a compound of formula



138 wherein R^{25} , R^{26} and R^{27} are, each independently, optional
139 substituents of the imidazole ring;

140 l) condensing a ketone of formula




142 with a thioamide of formula



144 in a reaction-inert solvent, thus preparing a compound of formula


145




146 wherein R^{28} and R^{29} are, each independently, optional substi-
 147 tuents of the thiazole ring, or where in the compound of formula
 148 (I-1-2) said thiazolyl ring is condensed with a five- or
 149 six-membered hetero- or carbocyclic ring, R^{28} and R^{29} taken
 150 together may form a radical of formula G^3 ;
 151 m) condensing a thioamide of formula




153 with a ketone of formula $\text{W-CHR}^{31}\text{---C(=O)-K-D}$, (XX), in a
 154 reaction-inert solvent, thus preparing a compound of formula




156 wherein R^{30} and R^{31} are, each independently, optional
 157 substituents of the thiazolyl ring;
 158 n) reacting an amide or thioamide of formula




160 with a >C=X^2 generating agent, in a reaction-inert solvent,
 161 thus preparing a compound of formula



163 o) cyclizing a urea or thiourea of formula




165 which in situ may be generated by reacting a reagent




167 with an amine




169 in a reaction-inert solvent, thus preparing a compound of formula




171 p) condensing an aniline of formula



173 with an acid of formula R^{13}COOH (XXVI), or a reactive
174 derivative thereof, in a reaction-inert solvent, thus preparing
175 a compound of formula



177 q) condensing an aniline of formula




179 with an amide of formula




181 in a reaction-inert solvent, thus preparing a compound of
182 formula (I-i-5);

183 r) condensing an aniline of formula




185 with an acetylene of formula $CH \equiv C-R^{15-a}$ (XXX), in a reaction-
186 inert solvent, thus preparing a compound of formula




188 s) condensing (XXIX) with a ketone of formula




190 in a reaction-inert solvent, thus preparing a compound of formula




192 t) condensing a reagent of formula




194 with a ketone of formula



196 in a reaction-inert solvent, thus preparing a compound of formula




198 u) condensing an amine of formula




200 with CS_2 , in a reaction-inert solvent, thus preparing a
201 compound of formula




203 v) reacting a reagent of formula $R^{23}-C(=NH)-W$ (XXXV) with an
204 amine of formula




206 in a reaction-inert solvent, thus preparing a compound of formula




208 w) cyclodesulfurizing a thioamide of formula




210 with an appropriate alkyl halide, metal oxide or metal salt in a
211 reaction-inert solvent, thus preparing a compound of formula





213 x) condensing an amine of formula




215 with a >C=X^2 generating agent, in a reaction-inert solvent,
216 thus preparing a compound of formula



218 wherein K is a bivalent radical of formula



221 wherein D represents a radical of formula



223 and R^{11} , R^{13} , R^{14} , R^{15} , R^{16} , R^{20} , R^{21} , R^{22} , R^{23} and R^{24} are, each
 224 independently optional substituents of the previously described
 225 bicyclic radicals and G^1 , G^3 , G^4 , G^5 and G^6 are, each independently,
 226 optionally substituted bivalent radicals, selected so that they form,
 227 combined with the five- or six-membered heterocycle to which they are
 228 attached, a bicyclic Het-system; or optionally converting the
 229 compounds of formula (I) into each other following art-known
 230 grouptransformation procedures, and, if desired, converting the
 231 compounds of formula (I) into a therapeutically active non-toxic
 232 acid-addition salt form by treatment with an appropriate acid or,
 233 conversely, converting the acid-addition salt into the free base form
 234 with alkali; and/or preparing stereochemically isomeric forms thereof.